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 Abstract 
Abstract  
 
The sialic acid binding immunoglobulin-like lectins (siglecs) comprise a family of 
receptors that are differentially expressed on leukocytes and other immune cells. 
Their molecular properties and the presence of tyrosine-based motifs suggest that 
they could be involved in fine-tuning the immune responses. Peripheral blood derived 
monocytes express siglec-3, -5, -7, -9, and -10 (1-10% monocyte population). Upon 
differentiation to macrophages a general trend of decrease in siglec-3, -5 and -9 and 
increase for siglec-7 expression was observed. The level of expression and degree of 
change during differentiation varied between individual donors. It is of special interest 
that siglec expression on mononuclear phagocytes is further regulated by different 
cytokines (IFN?: increased siglec-1 and decrease siglec-5, -7 and -9; IL-4: increased 
siglec-7 and 9 and decrease siglec-1). Six month monocyte surface siglec expression 
analysis of the 15 volunteers revealed that, siglec-9 shows the most diverse 
expression pattern as compared to the other monocyte limited siglecs, and these 
changes in expression pattern has direct relation with serum CRP levels. 
Furthermore, co-culturing monocytes with viruses revealed that mere presence of 
viral particles affects monocyte surface siglec expression profile. In addition, the viral 
dose and time of incubation contribute to these changes. The alteration in the siglec 
expression pattern in response to pathogens/tumour cells could be part of the host 
defence system. K562 erythroleukemia tumour cells were able to elicit early sialic 
acid (Sia) dependent cytokine secretion by mononuclear phagocytes. And this early 
cytokine secretion by mononuclear phagocytes upon co-culture with K562 surface 
Sia derivatives was confirmed with real time IL-6 mRNA synthesis. Furthermore, an 
accumulation of siglec-7 was observed at the cellular synapses between these two 
cell types. As siglecs are the only Sia recognising receptors present on innate 
immune system cells, and they could be involved in the observed Sia mediated 
activation processes. Here it is shown that siglec-7 could plays an important role in 
controlling the Sia mediated activation of mononuclear phagocytes by K562 tumour 
cells, as in presence of anti siglec-7 mAb activation of mononuclear phagocytes is 
reduced by 30-40%. 
Key words: Sialic acid, siglecs, ITIM, ITAM, Monocytes, Macrophages, Cytokines, 
IL-6, IL-1?, Viruses, Influenza virus, HAV-7, Coxsackie virus, NDV, CMV, K562 
tumour cells 
 Zusammenfassung  
Zusammenfassung 
 
Die Sialinsäure bindenden Immunglobulin-ähnlichen Lektine (Siglecs) umfassen eine 
Familie von Rezeptoren, die unterschiedlich auf Leukozyten und anderen 
Immunzellen exprimiert werden. Ihre molekularen Eigenschaften und das 
Vorhandensein von Tyrosin-basierten Motiven sind Merkmale, die sie mit anderen 
Rezeptoren gemeinsam haben, was darauf hindeutet, dass sie an der 
Feinabstimmung angeborener Immunreaktionen beteiligt sind. Periphere Blut-
Monozyten exprimieren Siglec-3, -5, -7, -9 und -10 (1-10% der 
Monozytenpopulation). Nach Differenzierung zu Makrophagen  wurde ein 
allgemeiner Trend zur Abnahme der Expression von Siglec-3, -5 und -9 und zum 
Anstieg bei der Siglec-7 Expression beobachtet. Die Höhe der Expression und der 
Grad der Veränderung während der Differenzierung ist zwischen den einzelnen 
Spendern unterschiedlich. Es ist von besonderem Interesse, dass die Siglec-
Expression auf mononukleären Phagozyten auch durch verschiedene Zytokine 
reguliert wird (IFN-? reguliert Siglec-1 hoch und reguliert Siglec-5, -7 und -9 runter; 
IL-4: reguliert Siglec-7 und 9 hoch und  Siglec-1 runter). Eine 6-monatige Analyse der 
Siglec-Expression auf der Oberfläche von Monozyten von 15 Freiwilligen hat gezeigt, 
dass Siglec-9 das verschiedenartigste Expressionsmuster im Vergleich zu den 
anderen Siglecs zeigt, was mit dem CRP-Spiegel im Serum korreliert. Eine Co-
Kultivierung von Monozyten mit Viren ergab, dass die bloße Anwesenheit von viralen 
Partikeln das Siglec-Expressionsprofil auf der Monocytenoberfläche beeinflußt. 
Zudem tragen die virale Dosis und die Inkubationszeit zu diesen Modifikationen bei. 
Die Veränderung im Siglec-Expressionsmuster in Reaktion auf Krankheitserreger / 
Tumourzellen könnte ein Teil des Abwehrsystems sein. K562-Erythroleukämie-Zellen 
konnten Sia-abhängig die Zytokinsezernierung von mononukleären Phagozyten 
induzieren. Diese frühe Zytokinausschüttung wurde mit real time-IL-6 mRNA-PCR 
bestätigt. Darüber hinaus war eine Ansammlung von Siglec-7 auf den zellulären 
Synapsen zwischen diesen beiden Zelltypen zu beobachten. Da Siglecs die einzigen 
Sia-erkennen Rezeptoren auf den Zellen des angeborenen Immunsystems sind, 
könnten sie bei den beobachteten Aktivierungsprozessen eine Rolle spielen. In der 
vorliegenden Arbeit wird gezeigt, dass Siglec-7 bei der Sia-vermittelte Aktivierung 
von mononukleären Phagozyten durch K562-Tumourzellen eine Rolle spielt, da anti-
Siglec-7 mAb die Aktivierung von mononukleären Phagozyten um 30-40% reduziert.
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1. Introduction 
1.1. Sialic acid binding immunoglobulin-like lectins  
Sialic acid binding immunoglobulin-like lectins, siglecs, form a family of cell surface 
receptors expressed on immune cells that mostly mediate inhibitory signalling 
responses (Hanasaki et al., 1995; Brinkman-Van der Linden EC et al., 2002; O'Reilly 
and Paulson, 2009; Crocker and Redelinghuys, 2008). Like other important inhibitory 
immune receptor families such as killer-cell immunoglobulin-like receptor and 
leucocyte immunoglobulin-like receptor, siglecs are transmembrane molecules that 
contain inhibitory signalling motifs called immunoreceptor tyrosine based inhibitory 
motifs (ITIMs) in their cytoplasmic tails and immunoglobulin superfamily domains in 
their extracellular parts (Kelm et al., 1994; Sgroi et al., 1993; Crocker and Varki, 
2001; Crocker et al., 2007; von G.S. and Bochner, 2008; Walker and Smith, 2008; 
Tedder et al., 2005; Crocker and Redelinghuys, 2008; Collins et al., 2006)(Figure 
1.1). Compared to other immunoglobulin super-family proteins a unique feature of 
siglecs is their specificity towards sialylated carbohydrates, unlike other immune 
receptors that bind to protein determinants. Siglecs play a wide range of roles in the 
immune system. Sequencing of the human genome gave rise to the discovery of new 
members, expanding the group from the well-characterized conserved members, 
sialoadhesin, CD22, CD33 and myelin-associated glycoprotein (MAG), to the rapidly 
evolving CD33-related siglec (CD33rsiglec) subfamily that are expressed by different 
cell types (von G. S. and Bochner, 2008) (Figure1. 1 and Table 1.1). 
 
1.2. CD33-related siglec and their importance in the immune responses 
The CD33rsiglecs are mainly expressed by the cells of the innate immune system, 
such as neutrophils, eosinophils, monocytes, macrophages, NK cells, dendritic cells, 
and mast cells (Table. 1.1). CD33rsiglecs have been described to modulate the 
immune system, like inhibition of cellular proliferation (Vitale et al., 1999; Xiong et al., 
2009), induction of apoptosis (Nutku et al., 2005; von G. S. et al., 2005), inhibition of 
cellular activation (Paul et al., 2000; Ulyanova et al., 2001; Avril et al., 2004; Ikehara 
et al., 2004; Avril et al., 2005), and induction of pro-inflammatory cytokine secretion 
(Lajaunias et al., 2005). 
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Figure 1.1: Nomenclature and key structural characteristics of human siglecs. 
DAP12 domains are illustrated as a + in the transmembrane region, co-associating with siglec-
14 and siglec-15. See key for symbols representing cytoplasmic signalling motifs and 
expression. 
 
CD33 and siglec-7 have been shown to inhibit proliferation of haematopoietic cells 
and myeloid leukaemic cells in transfected Ba/F3 cells (Orr et al., 2007). Siglecs-8 
and -9 induced cell-death (Nutku et al., 2003; von G. S. et al., 2005) is enhanced in 
the presence of cytokines that normally help cell survival. The above indicates a very 
complex interplay between cytokine receptor and siglec signalling pathways (von G. 
S. et al., 2006). CD33rsiglecs can also function as endocytic receptors in the 
clearance of sialylated antigens and/or in promoting or inhibiting antigen presentation 
(Lock et al., 2004; Avril et al., 2006; Walter et al., 2008; Nguyen et al., 2006; 
Biedermann et al., 2007) 
 
1.3. CD33-related siglec attenuate innate immune responses 
The ability of human siglecs to bind sialic acids (Sia) present on the same cell 
surfaces would expose humans to pathogens. This possibly reinvented Sia via 
convergent evolution, leading to inhibitory siglec function so as to dampen innate 
immune responses. Indeed, many microorganisms that express Sia (Neu5Ac) appear 
to be human-specific commensalisms, becoming pathogenic when circumstances 
allow (Vimr et al., 2004). For example, Group B Streptococcus expresses a Sia-
containing capsule that engages human neutrophil (siglec-9), dampening its 
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responses (Weiman et al., 2009). Other sialylated pathogens that are recognized by 
siglecs (Jones et al., 2003), likely with similar outcomes (Khatua et al., 2009). 
Notably, such pathogens would be a strong selective force, because they often affect 
fetuses, infants and young adults and frequently cause lethal brain infections (Vimr et 
al., 2004) 
 
Table 1.1: Siglecs expression on various human cells types (von G.S. and Bochner, 2008) 
 Siglec 
Cell type 1 2 3 4 5 6 7 8 9 10 11 14* 15 
B cell  +   ± ±    +  +  
Basophile   +  + +  ±    +  
CD8+ T cell       +  +     
CD34+ cell¶   +  +    + +  +  
Dendritic cell   +    +  + +    
Eosinophils        +  ±    
Epithelial cell +             
Macrophage +  +  +      + + + 
Mast cell†  ± +  + +  +    +  
Microglia cell            +  
Monocyte   +  +  +  + + + + + 
Neutrophil   +  +    +   +  
NK cell       +  ± +    
Oligodendrocyte    +          
Placental 
trophoblast 
     +        
Schwann cell    +          
* Expression is probably similar to siglec-5, but this has not yet been confirmed; ± Expressed 
intracellular or only weakly on the cell surface 
 
1.4. Siglecs and Sia binding specificities 
Siglecs bind to Sia with different specificities based on the linkage and the underlying 
sugars (Strenge et al., 2001; Blixt et al., 2003) (Table 1.2). Although siglec ligands 
were identified using synthetic Sia probes, the in vivo natural ligands are yet to be 
characterized. Generally Sia binding sites of the siglecs are often masked by 
endogenous glycoproteins from the same cell surface making it difficult to determine 
the function of Sia binding in intact cells. One possibility to prevent Sia binding by 
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siglecs can be achieved by sialidase treatment or by cellular activation (Razi and 
Varki, 1999). Many different studies investigating the glycan specificities of different 
siglecs suggest that at least in vitro, both sialylated glycoprotein and/or gangliosides 
could function as potential binding partners (Collins et al., 1997; Crocker et al., 1991; 
Hanasaki, 1995; Kelm et al., 1994; Sawada et al., 1999; Sgroi et al., 1993; Strenge et 
al., 1999; Yamaji et al., 2002; Strenge et al., 2001). 
 
Table 1.2: Siglecs preference for different sialoside structures (vonG.S.  and Bochner, 2008) 
siglec Sialoside preference 
siglec-1/Sn 
 
siglec-3/CD33 
 
siglec-5 
 
siglec-7  
siglec-8 
 
siglec-9 
 
siglec-10 
 
Colour coding: purple diamond, N-acetylneuraminic acid; pale blue diamond, N-
glycolylneuraminic acid; yellow circle, galactose; yellow square, N-acetylgalactosamine; blue 
square, N-acetylglucosamine; red triangle, fucose; red S, sulphate. 
 
 
 
?3 ?4 
?6 ?4 
?8 
?6 
?8 ?3 ?4
?3 ?4
6S
?3
?3 ?4
6S
?3
?3 ?4
?6 ?4
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1.5. Sialic acid and its biological role 
In higher invertebrates the outer ends of glycan chains are often covered by Sia 
(Varki and Gagneux, 2009; Schauer, 2009). Biosynthetic pathways for these nine 
carbon backbone molecules likely evolved from those for ancestral nonulosonic acids 
(Lewis et al., 2009). Although Sias are rare in other taxa, they are ubiquitous on all 
vertebrate cell surfaces and are essential for embryonic development (Schwarzkopf 
et al., 2002). Indeed, they mediate many critical endogenous functions based on their 
physical properties and their recognition by intrinsic receptors (Varki and Gagneux, 
2009; Schauer, 2009). Also, Sias are used by complement factor H (Pangburn et al., 
2000) and by siglecs (Angata et al., 2006; Crocker and Redelinghuys, 2008) as 
signals for self recognition in the vertebrate innate immune system. However, given 
their location and abundance, Sias are equally targets for extrinsic receptors of 
numerous pathogens (Varki and Gagneux, 2009). Sias have been modified 
repeatedly via convergent evolution by microbes that interact with vertebrates 
(Weiman et al., 2010; Vimr and Steenbergen, 2006). Such imitation allows 
microorganisms to use Sias not only to mask themselves from the complement and 
adaptive immune systems (Schauer, 2009; Pangburn et al., 2000),. but also to 
engage siglecs, dampening the innate immune response (Carlin et al., 2009). For all 
these reasons, Sias are at the nexus of an evolutionary arms race between the 
vertebrate hosts and their pathogens. This competition may also explain why there 
are different kinds of Sias, each presented in several different linkages to the 
underlying monosaccharide, on a variety of different types of glycans (Varki, 2010; 
Schauer, 2009). 
 
1.6. Regulation of siglec function with cis- and trans-ligands 
Very little is known about the nature of physiologically important ligands and counter-
receptors of the siglec family. This is because siglec binding sites are typically 
blocked by cis- interactions with other glycan ligands expressed on the same cell 
surface (Collins et al., 2004). In nature, cis-ligands may dominate over trans-ligands 
and thus modulate the biological activities of siglecs (Collins et al., 2006). CD22 on B 
cells gets delocalized at the contact site with the cells expressing CD22 ligands 
(Lanoue et al., 2002). The high-affinity synthetic Sia probes can overcome CD22 cis-
ligands interaction (Nicoll et al., 2003). B-cell activation in response to antigen-
presenting cells is suppressed if antigen and the CD22 ligand are expressed on the 
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same cell (Yeaman et al., 2002). Siglec-7 dependent reduction in NK-cell cytotoxicity 
was observed with target cells over-expressing ?2–8-linked glycans. Cytotoxicity was 
increased by sialidase treatment, which cleaves the cis-interacting ligands from the 
cell surface (Ravetch and Lanier, 2000). The above examples illustrate the role 
played by cis- and trans-ligands in siglec function. 
 
 
Figure 1.2: Schematic presentation of siglecs in native cis- and trans-interactions (adapted 
from Crocker P presentation) 
Most siglecs are masked on the cell surface because they are involved in cis-interactions with 
Sia expressed on the same cell surface. Sialidase, which cleaves the cis-interacting siglec 
ligands, or in some cases cellular activation can also remove siglecs from cis-interaction, 
which allows them to make interactions with trans-ligands. Trans-interactions might occur 
during an encounter with another cell or a pathogen expressing higher affinity ligands that can 
compete with the cis-interactions. 
 
1.7. The role of CD33rsiglecs in regulating cytokine production 
Over-expression of siglec-9 in macrophage-like cell lines suppresses the Toll-like 
receptor (TLR) -dependent production of pro-inflammatory cytokines, tumour necrosis 
factor-? (TNF?) and IL-6, in macrophages followed by lipopolysaccharide (LPS) or 
peptidoglycan stimulation (Ando et al., 2008). These effects were abolished when the 
critical tyrosine residues in ITIM and ITIM-like motifs of siglec-9 were mutated (Ando 
et al., 2008). These observations are consistent with the studies of human monocytes 
in which siRNA-mediated knockdown of CD33, led to spontaneous secretion of pro-
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inflammatory cytokines (Lajaunias et al., 2005) and collectively they indicate that 
ITIM-bearing CD33rsiglecs may restrain the pro-inflammatory functions of 
macrophages. Cross-talk between CD33rsiglecs and TLR signalling pathways was 
also demonstrated for siglec-H (Blasius and Colonna, 2006; Blasius et al., 2006). 
Following cross-linking of siglec-H expressed in pDC (Dendritic cells) with antibodies, 
type-I interferon production in response to TLR-9 ligation with CpG was strongly 
inhibited. This paradoxical inhibition of cytokine production via DAP12-coupled 
‘activating’ receptors has been observed with several pDC expressed receptors and 
may be the result of a signalling pathway in pDCs shared with B cells that 
suppresses type 1 interferon production (Sjolin et. al, 2006).  
Siglec-E is a typical inhibitory mouse siglec expressed on myeloid cells (Zhang et al., 
2007; Yu et al., 2001). Boyd et al., (Boyd et al., 2009), demonstrated a TLR- and 
MyD88-dependent up-regulation of siglec-E on mouse bone-marrow-derived 
macrophages. Cross-linking siglec-E using specific antibodies shows reduction in 
production of nuclear factor-kB-dependent cytokines, TNF? and IL-6, in response to 
LPS stimulation. This suggests that siglec-E up-regulation on macrophages 
represents a negative feedback pathway that limits the inflammatory response to LPS 
signalling. A major drawback of receptor over-expression and the use of antibodies to 
cross-link siglecs is that they may trigger non-physiological signalling pathways. 
Siglecs are normally masked on the cell surface via cis-interactions with cell-
expressed sialic acids, which limits the ability of exogenous trans-ligands to induce 
clustering at the cell surface.  
 
1.8. Importance of ITIM-like motifs in siglec function 
Most CD33rsiglecs have two conserved cytoplasmic tyrosine-based motifs, 
comprising a membrane-proximal ITIM and a membrane-distal ITIM-like motif. 
Achieving balance between positive and negative signals within the immune system 
is very important (Ikehara et al., 2004; Nguyen et al., 2006). Loss of inhibitory 
signalling is often associated with autoimmune reactivity and unchecked 
inflammatory responses, illustrating the essential role such systems play in the 
immune system (Paul et al., 2000; Ulyanova et al., 2001; Avril et al., 2004; Avril et al., 
2005; Taylor et al., 1999; Yu et al., 2001).  
The presence of ITIM-like motifs in the cytoplasmic regions of most of the siglecs 
strongly suggest that they play a role in siglec mediated cellular responses (Crocker 
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and Varki, 2001; Crocker and Varki, 2001). Regulation of ITAM-dependent immune 
responses by CD33rsiglecs has been shown in various cell types, including 
transfected T cells, mast cells and myeloid cells. Interestingly, both primary human T 
cells and Jurkat cells, which normally lack significant levels of CD33rsiglecs, showed 
decreased T-cell-receptor-dependent activation following over-expression of siglec-5, 
siglec-7 or siglec-9 (Avril et al., 2004; Avril et al., 2005; White et al., 2005; Taylor et 
al., 1999; Biedermann et al., 2007). Mutagenesis experiments with CD33rsiglecs 
have shown that the ITIM dominates over the ITIM-like motif, both for the recruitment 
of SHP1 and SHP2 and for inhibitory signalling functions (Jones et al., 2003; 
Monteiro et al., 2005; Nitschke, 2009; Avril et al., 2006). However, the ITIM-like motif 
was required for optimal recruitment of SHP1, but not of SHP2, and could therefore 
be important in fine-tuning downstream signalling from CD33rsiglecs. The ITIMs of 
CD33rsiglecs are important for other functions, including the suppression of siglec-
dependent adhesion to sialylated ligands and endocytosis (Janicke and Mannel, 
1990). In addition, robust binding to SHP1 and SHP2 requires tyrosine 
phosphorylation of both the ITIM and ITIM-like motif. It has also been suggested, that 
sialylated pathogens modulate leukocyte activation through ITIM-mediated signalling 
of CD33rsiglecs, thereby benefiting the pathogen by dampening inflammatory and 
immune responses (Putz and Mannel, 1995; Westenfelder et al., 1993). 
Mononuclear phagocytes are innate immune cells with well-established roles in the 
primary response to pathogens, but also in tissue homeostasis, coordination of the 
adaptive immune response, inflammation, resolution, and repair mechanisms. These 
cells recognize danger signals through receptors capable of inducing specialized 
activation programs. The classically known macrophage activation is induced by 
IFN?, which triggers a harsh pro-inflammatory response that is required to kill 
intracellular pathogens. Macrophages also undergo alternative activation by IL-4.  
 
1.9. Sia-dependent functions of macrophages 
Several studies investigating potential roles of Sia in macrophage functions have 
been addressed using the interaction of macrophages with tumour cells. Cameron et 
al. showed that macrophage-mediated cytotoxicity to tumour cells of patients having 
osteogenic sarcoma correlates with the degree of Sia expression on the tumour cells 
(Cameron, 1983). Only cells with high Sia content were susceptible to macrophage-
mediated cytotoxicity. Several other studies then confirmed that macrophages 
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recognise tumour cells by sialylated structures and that this binding induces TNF? 
and IL-1 production by macrophages. The plasma membranes of Jurkat or K562 cells 
are able to induce TNF? production by monocytes indicating that the activating 
structure is exposed on the surface of the tumour cells (Westenfelder et al., 1993). 
The activating capacity of such tumour cell membranes was abolished with the 
destruction of sialylated glycans by treating the tumour cells with periodate, sialidase 
or PNGase F, prior to exposure to macrophages (Sawabe et al., 2000) but not with 
glutardialdehyde treatment (Hakomori, 1991; Ito et al., 2001; Saldova et al., 2008). 
Another important Sia function of monocytes and macrophages is the clearance of 
damaged and apoptotic cells by phagocytosis. Phagocytosis of oxidized T-cells and 
erythrocytes by human monocytic leukemia THP-1 cells differentiated into 
macrophages is Sia-dependent and can be inhibited by sialidase treatment of the 
oxidized cells (Colotta et al., 1992; Mantovani et al., 1992; Mattoli et al., 1991; Farrar 
et al., 1982).  
 
1.10. Tumour associated macrophages 
Phenotypic changes in malignancy often correlate with a dramatic transformation of 
cellular glycosylation pattern due to changes in the activity of one or more of the 
glycosyltransferases during the process of transformation from normal to tumour cells 
(Oberling, 1997). This may in turn be able to influence the tumour cell recognition by 
siglecs present on mononuclear phagocytes. As a result, there is increased cytokine 
secretion which finally may influence disease progression. Most malignant tumours 
contain numerous macrophages as a major component of their leukocytic infiltrate. 
The tumour microenvironment of tumour-associated macrophages (TAMs) can 
influence the tumour growth in two directions (1) they can co-exist with the malignant 
cells in a symbiotic manner and contribute to tumour metastasis and proliferation or 
(2) they can destroy neoplastic cells and present tumour-specific antigens to other 
leucocytes, leading to the induction of a specific immune response (Valdez and 
Perdigon, 1991). The monocyte derived macrophages can exhibit very high antibody-
dependent and independent specific cytotoxicity for tumour cells; these macrophages 
are capable of phagocytosis of these cells and can present antigen on their surface 
(Gordon, 1998; Goerdt et al., 1999). Since mononuclear phagocytes are the first 
immune cells getting in contact with the tumour cells, siglecs could play an important 
role in tumour cell recognition and activation of the immune system. 
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TAMs are often in an activated state compared to normal tissue macrophages 
(Fenton et al., 1992; Dickensheets and Donnelly, 1997). Macrophages can be 
activated either by IFN?, the dominant cytokine released by type 1 T-helper cells or 
by IL-4, the dominant cytokine released by type 2 T-helper cells. In general, 
activation of macrophages by IFN? enhances the anti-microbial activity, whereas IL-4 
induces an alternative activation which leads to efficient antigen presentation to B-
cells (Cameron and Churchill, 1982). Interestingly, IL-4 can diminish the macrophage 
response to IFN? (and other type I lymphokines), whereas IFN? has comparable 
suppressive activity targeting the alternative response pattern induced by IL-4 (Putz 
and Mannel, 1995; Janicke and Mannel, 1990; Westenfelder et al., 1993). Several 
other studies have confirmed that the induced production of TNF? and IL-1? by 
macrophages is mediated by sialylated glycoconjugates, as indicated by plasma 
membranes of Jurkat or K562 cells being able to induce cell activation (Shrive et al., 
1996; Oliveira et al., 1979).  
 
1.11. Siglecs as immuno-modulators and targets for pathogens 
High Sn expression is seen in chronic inflammatory diseases such as rheumatoid 
arthritis (Crocker and Redelinghuys, 2008), atherosclerosis (Gijbels, et al., 1999) and 
models of inherited demyelinating diseases of the nervous system (Kobsar et al., 
2006). In contrast with the CD33rSiglecs, there is currently little evidence that Sn 
mediates signalling functions via its trans-membrane tail or cytoplasmic region which 
lacks obvious signalling motifs. Furthermore, cell–cell and cell–matrix interactions are 
accentuated further by the extension of the N-terminal V-set domain beyond the 
reach of shorter cis-interacting inhibitory siglecs closer to the plasma membrane. Sn-
deficient mice exhibit reduced CD4+ T-cell and inflammatory responses in a model of 
autoimmune uveoretinitis. They also exhibited reduced CD8+ T-cell and macrophage 
recruitment in models of inherited demyelinating neuropathy in both the central and 
peripheral nervous systems (Crocker et al., 2007). IFN?, a potent antiviral cytokine 
and immune modulator, was shown to induce Sn expression in monocytes which 
normally do not express the receptor and also to increase Sn expression in 
macrophages (York et al., 2007). IFN? produced by activated T-cells and NK cells 
has also been shown to induce Sn expression on monocytes (Rempel et al., 2008; 
Crocker and Redelinghuys, 2008). 
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Siglecs has also been shown to facilitate pathogen interactions. For example, Sn and 
siglec-5 can promote macrophage uptake of sialylated strains of Neisseria 
meningitidis (Crocker, 2005) and functions in endocytosis of the 
macrophage/monocyte-tropic porcine reproductive and respiratory syndrome virus 
(PRRSV)(Delputte et al., 2007; Delputte et al., 2007; Delputte and Nauwynck, 2006). 
During the acute period of HIV-1 infection, IFN? is produced by NK cells and T-cells, 
and IFN? is released by pDCs (plasmacytoid dendritic cells) as part of the antiviral 
response. This may lead to induction of Sn on monocytes, which in turn binds avidly 
to the virus in a sialic acid-dependent manner. This may permit the effective 
transinfection of permissive cells and the delivery and distribution of HIV-1 to target 
cells in the periphery. Several CD33rsiglecs can interact with sialic acids on N. 
meningitidis, C. jejuni, group B Streptococcus and Trypanosoma cruzi (Jones et al., 
2003; Monteiro et al., 2005; Avril et al., 2006; Carlin et al., 2009). Siglec-dependent 
uptake of these pathogens could potentially benefit the host by promoting pathogen 
destruction and antigen presentation. It has also been suggested, but not proven, 
that sialylated pathogens modulate leukocyte activation through ITIM-mediated 
signalling of CD33rsiglecs, thereby benefitting the pathogen by dampening 
inflammatory and immune responses. 
The newly evolved members of the human CD33rsiglecs group such as Siglec-14 
and -16 have revealed the existence of paired inhibitory and activating receptors 
within this gene family. Although the primordial functions of the CD33rsiglecs are 
likely to be ITIM-dependent dampening of immune responses and endocytosis, the 
emergence of ITAM-coupled paired receptors points towards a counter-strategy of 
the host towards sialylated pathogens. Clearly there is an intricate interplay between 
pathogens and the multiple immune receptors that determines the outcome of the 
immune response, and siglecs are part of this complex network that also includes 
many other lectin-like receptors. It will be a related challenge to understand the 
impact of pathogen sialylation on siglec-mediated host immune responses, an issue 
that may give insights into the evolutionary pathways that have led to the 
diversification of this family. It will also be of interest to see whether the cytokine 
dependent induction of CD33rSiglecs has evolved primarily to promote macrophage–
host cell interactions in adaptive immunity or whether this is a determining factor in 
host resistance and/or susceptibility to certain sialylated pathogens. 
 
 Introduction 12 
1.12. Aim of the project 
The CD33rsiglecs are mainly expressed by the cells of hematopoietic system, and 
have been described to alter the immune responses. It’s not very clear how these 
responses are triggered or controlled. The unique ability of siglecs, specificity 
towards sialylated carbohydrates may be either used to mask pathogen receptor 
sites or this specificity towards Sia derivatives could be exploited by pathogens to 
invade the immune system. This is because in native conditions siglec binding sites 
are typically blocked by cis-interactions with glycans expressed on the same cell 
surface. These cis-interactions can be overcome in presence of higher affinity binding 
partner present on adjacent tumour cells or pathogen. The resultant involvement in 
trans-interactions may result in trigging immune responses. These interactions and 
siglec specificities towards underneath glycane linkages could be better understated 
through binding and inhibition assays. As siglec is a trans-membrane protein for 
easier handling, the first three domains involving important Sia binding domain of 
siglecs (-5, -7, -8, -9 and -10) cloned into the pDEF vector and stably transfected into 
CHOLec1 cell. CHOLec1 mammalian cells cannot synthesize complex 
oligosaccharide which is advantageous for binding and inhibition assays which can 
be hampered by glycan heterogeneity. In-vivo experiments with erythroleukemia 
K562 tumor cell and Sia free siglecs will help to identify and isolate trans-binding 
partners present on K562 cells. Furthermore these Sia free siglecs can be screened 
for potential synthetic or biological inhibitors in binding and inhibition assays. Sia free 
siglecs were screened for their quality and functionality before using them in above 
mentioned experiments. 
As described earlier siglecs show complex expression pattern on hematopoietic cells. 
Some reports suggests that siglec over-expression in macrophage-like cell lines 
suppresses the receptor dependent production of pro-inflammatory cytokines. It will 
be interesting to investigate if changes in inflammatory marker levels influence the 
siglec expression. Preliminary data show that siglec expression level on monocytes 
isolated from different individuals is not same. Long-term monocytes surface siglec 
profiling will give a hint in this direction. The data obtained can be plotted against 
serum CRP levels, as CRP levels get elevated in response to immune response. This 
will enlighten the link between immune system and siglec expression. 
 The immune compromised system established by co-culturing purified virus 
(enveloped and non enveloped) together with monocytes in suspension culture. The 
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resultant time and virus concentration mediated changes in monocyte surface siglec 
expression will give direct evidence. These experiments with virus particles will help 
to assess the direct role of pathogen mediated changes on monocyte surface siglec 
expression. 
Siglecs are also described to be involved in inhibition of cellular proliferation, 
induction of apoptosis, inhibition of cellular activation, induction of pro-inflammatory 
cytokine secretion. The primordial functions of theCD33rsiglecs are likely to be in 
ITIM dependent dampening of immune responses and endocytosis. Clearly there is 
an intricate interplay between pathogens and the multiple immune receptors that 
determines the outcome of the immune response, and siglecs are part of this 
complex network. A related challenge will be to understand the impact of pathogen 
sialylation on siglec-mediated host immune responses. It will also be of interest to 
see whether the cytokine dependent induction of CD33rSiglecs has evolved primarily 
to promote macrophage–host cell interactions in adaptive immunity or whether this is 
a determining factor in host resistance and/or susceptibility to certain sialylated 
pathogens. 
Macrophages are known to interact with sialylated trans-ligands on tumour cells, 
which induce Sia-dependent activation of the macrophages. Since no Sia-binding 
lectins other than siglecs are known to be present on macrophages, it is likely that 
this activation is mediated by siglecs. Previous experiments showed that Siglec-7 and 
siglec-10 bind with high affinity to the K562 erythroleukemia cell line, indicating that 
these tumour cells express high affinity binding partners for these two siglecs. It will 
be interesting to see, if one tumour-specific siglec binding partner can be isolated 
from different tumour cells. Such an interaction could describe a new pathway 
through which macrophages can distinguish between normal and neoplastic cells. To 
prove this hypothesis, macrophage-mediated anti-tumour activity such as IL-6 or IL1? 
cytokine production can be monitored. It will be also of an interest to see, if after 
blocking the receptor siglec macrophage mediate the anti tumour response with 
same efficiency.  In addition, it will be interesting to investigate which of the 
CD33rsiglecs mediate this interaction. The project aims to investigate “How do 
carbohydrates and siglecs regulate the Sia mediated immune response by 
monocytes and macrophages?” 
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2. Materials 
2.1. Antibodies and plant lectins 
The concentrations and dilutions for reagents are according to the guidelines 
mentioned on product data sheet. 
 
2.1.1. Antibodies for flow cytometry 
Name Manufacturer Concentration/Dilution 
FITC-mouse anti human 
CD 14 monoclonal 
antibody 
Immunostep research 1mg/mL/1:50 
PE-conjugated Goat Anti-
mouse IgG antibody 
Jackson Immunoresearch 
Laboratories, INC. 
1mg/mL/1:100 
Mouse anti human siglec-
(1, 3, 5, 7, 8, 10) 
monoclonal antibody 
Generous gift from Prof. 
Dr. Paul Crocker 
(cell culture supernatant) 
N.A./1:25 
Mouse Anti human siglec 
9 mAb 
Generous gift from Prof. 
Dr. Paul Crocker 
(cell line) 
1mg/mL/1:100 
PE-Streptavidin  1mg/mL/1:100 
 
2.1.2. Antibodies for immunodetection 
Name Manufacturer Concentration/Dilution 
POD-donkey anti mouse IgG  Affinipure 0.4mg/mL 
Biotin-goat anti human IgG, Fc?-
Fragment 
Affinipure 0.64μg/mL 
Goat anti human siglec-(5, 7, 8, 
9, 10) polyclonal antibody 
AG Kelm Different for each antibody 
 
2.1.3. Plant lectins and detection reagents 
Name Manufacturer Concentration/Cilution 
biotinylated MAL II (Maackia 
amurensis lectin II) 
Vector Laboratories 10g/mL in 0.2% BSA 
biotinylated PNA (Peanut 
agglutinin) 
Vector Laboratories 10g/mL in 0.2% BSA 
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biotinylated SNA 
(Sambucus nigra bark 
agglutinin) 
Vector Laboratories 2g/mL in 0.2% BSA 
Peroxidase conjugated) 
Vector Laboratories? ABC 
reagent (Vectastain®) 
Vector Laboratories 1:1 in 0.2% BSA in TBS-T 
 
2.2. Chemicals and consumables 
2.2.1. General chemicals, enzymes, and consumables 
All solutions were made up in doubly deionized water (ddH2O), from an Ultra Clear® 
Inegra UV Plus water purification system (SG, Barsbüttel). Media and buffer solutions 
were autoclaved (30 min, 121°C) or sterile filtered through (0.22 μm) filters. Unless 
otherwise stated, chemicals are of analytical grade. Cell culture media and reagents 
were obtained from Gibco, Sigma etc; whereas materials and equipment for SDS-
PAGE are from the BIO-RAD (Hercules, California, USA) company. DNA-modifying 
enzymes, DNA polymerases and molecular weights standards used were from MBI 
Fermentas, New England Biolabs, Promega and Gibco. 
Serological pipettes, plastic tubes, cell culture dishes, pipette tips, and 1.5mL 
microfuge tubes were purchased from Sarstedt, 0.2mL PCR tubes were from Biozym. 
Multichannel pipettes 12- and 8-channel, multichannel pipette tips (20-300μL), and 
cuvettes (220-1600nm) were purchased from Eppendorf, Hamburg, Germany. 
 
2.3. Materials for the affinity chromatography 
Name Manufacturer 
 Chromatography columns Poly Prep? BIO-RAD(Hercules, 
California, USA) 
NHS-Sepharose Fast Flow (capacity 35mg protein/mL 
matrix 
Amersham 
Bioscience 
Protein A-Sepharose Fast Flow (capacity 35mg IgG/mL 
matrix) 
Amersham 
Bioscience 
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2.4. Special materials and reagents 
Name Manufacturer 
Acetonitrile (methyl cyanide) Sigma 
Base pair-/Molecular weight standards (80-
10000 bp) 
MBI Fermentas 
BSA (fraction V) PAA Laboratories 
Cellline CL350 or CL1000 fermenter Integra 
Dialysis tubing (Visking ® 8/32, exclusion limit 
10 kD) 
Serva 
ExGen500 in vitro transfection reagent MBI Fermentas 
FDP (fluorescein diphosphate) MoBiTec (Gibco) 
Hygromycin PAA Laboratories 
Skimmed milk Heirler GmbH 
X-ray film Hyper film ECL Amersham Bioscience 
Protein molecular weight standard (pre-stained + 
unstained) 
MBI Fermentas 
PVDF membrane Hybond-P Amersham Bioscience 
PAA-?2,3-sialyllactose Gift from Dr. Strenge 
PAA-?2,6-sialyllactose Gift from Dr. Strenge 
PAA-Sialyl-Lewisx Gift from Dr. Strenge 
PAA-Sialyl-Lewisa Gift from Dr. Strenge 
PAA-6´-O-sulfo-lactose Gift from Dr. Strenge 
Trypsin (Sequencing Grade Modified) Promega 
Vibrio cholera sialidase (VCS) 1 unit/mL Dade Behring 
Bode Korsolex® Basic Bode Chemie Hamburg 
Bode Baktobod® Bode Chemie Hamburg 
Minisar®Sterile-EO single use (0.20 μm) Sartorius Biotech, Göttingen 
Vivaspin 6 Sartorius Biotech, Göttingen 
Vectaspin Micro, 0.2μm Whatman® Schleicher & Schuell 
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2.5. Kits 
Name Manufacturer 
BCA Protein Assay Reagent Pierce 
ECL Western blotting detection reagent Amersham Bioscience 
FastPlasmid Mini Kit? Qiagen 
HiSpeed Plasmid Midi Kit? Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit? Qiagen 
Vectastain? ABC Kit Vector Laboratories 
 
2.6. Bacteria, viruses and cell lines 
2.6.1. Bacterial and virusstrains 
Name Manufacturer/donor 
?DH5 Escherichia coli Dr. Klipp Bochum 
XL1-blue Escherichia coli Stratagene 
influenza virus strain A/PR8/34 Kind gift from Prof. Andreas Dotzauer 
Coxsackie B2 virus Kind gift from Prof. Andreas Dotzauer 
Newcastle Disease Virus (NDV) Kind gift from Prof. Andreas Dotzauer 
Cytomegalovirus (CMV) Kind gift from Prof. Andreas Dotzauer 
human hepatitis A virus-7 (HAV-7) Kind gift from Prof. Andreas Dotzauer 
human hepatitis A virus-glioblastoma 
(HAV-GBM) 
Kind gift from Prof. Andreas Dotzauer 
 
2.6.2. Cell lines 
Name Manufacturer/donor 
CHOK1 cell line (Subclone of Chinese 
Hamster Ovary, CHO Cells) 
DSMZ, Heidelberg 
CHOLec1 cell line (Subclone of 
Chinese Hamster Ovary cells) 
DSMZ, Heidelberg 
Foetal Rhesus monkey Kidney cell line 
(FRhK-4 cell line) 
DSMZ, Heidelberg 
K8 mouse hybridoma cell line producing 
anti hu siglec-9 monoclonal antibody 
Kind gift from Prof. Dr. Paul Crocker  
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2.7. Media 
Name Components 
LB medium (With Ampicillin) 15g tryptone, 5g yeast extract 
5g NaCl 
makeup volume to 1L ddH2O 
autoclaved, (+ 60μg/mL ampicillin) 
LB-agar plates (+Amp) 15g agar in 1L LB medium (+ 60g/mL 
ampicillin) 
RPMI medium RPMI-1640 liquid medium (without glutamine) 
?-MEM medium 10.17g ?-MEM powder 
2.2g NaHCO3. fill up to1L ddH2O, sterile filter, 
store at 4°C  
DMEM medium (Dulbecco’s 
modified Eagle’s medium) 
Supplement list 
1% (v/v) nonessential amino acid solution 
(MEM) 
1mM sodium pyruvate MEM 
0.07% L-glutamine 
0.05mM 2-mercaptoethanol 
100U/mL penicillin 
100U/mL streptomycin 
10-10% (v/v) FCS, heat inactivated 
 
2.8. Physiological buffers 
Name Components 
HBS (HEPES buffered saline) 10mM HEPES pH 7.4/150mM NaCl 
HBS-T (HBS with Tween20) HBS with 0.05% (w/v) Tween 20 
HBA (HBS with BSA) HBS with 0.5% (w/v) BSA 
PBS (phosphate buffered saline) 137mM NaCl/2.7mM Na2HPO4, 1.5mM 
K2HPO4 
PBA (PBS with BSA)  PBS with 0.5% (w/v) BSA 
HBS-/PBS-Azid HBS/ PBS with 0.02% (v/v) sodium azide 
(2% (w/v)) 
TBS (Tris buffered saline) 10mM Tris-HCl pH 7.4/150mM NaCl 
TBS-T (TBS with Tween20) TBS with 0.15% (w/v) Tween 
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TBE buffer (1L 10? solution) 108g Tris/55g boric acid/40mL 0.5M 
EDTA pH 8/ad 1L ddH2O 
TMF buffer (100mM CaCl2?2H2O/40mM 
MnCl2?4H2O/50mM RbCl ad ddH2O) 
100mM CaCl2 ?2H2O/40mM MnCl2 
?4H2O/50mM RbCl ad ddH2O 
0.1M bicarbonate buffer, pH 8.3 0.1M NaHCO3, 0.5M NaCl  
AoAB (Alsevier's medium without 
antibiotics)  
7.94g sodium citrate/NaCl 4.5g/20.56g 
glucose pH 6, 1 ad 1L ddH2O  
4-fold separation gel buffer 1.5M Tris-HCl pH 8.7 with 0.4% SDS 
4-fold stacking buffer 0.5M Tris-HCl pH 6.8 with 0.4% SDS 
2-fold-reducing sample buffer  125mM Tris-HCl pH 6.8/20% (w/v) 
glycerol/0.05% (w/v) bromophenol 
blue/4% (w/v) SDS/10mM DTT 
electrophoresis running buffer  25mM Tris/192mM Glcyin/0.1%/10% 
SDS 
blotting buffer 25mM Tris/192mM glycine/20% (v/v) 
methanol 
Loading buffer  250mM Na2EDTA, 87% (v/v) glycerol, 
0.5mg/mL (w/v) bromophenol blue 
Coomassie Brilliant Blue solution 0.5% (w/v) SERVA Blue R/40% (v/v) 
methanol/10% (v/v) acetic acid/Solution 
then filtered through a folded filter 
Coomassie distaining solution 40% (v/v) methanol/10% (v/v) acetic 
acid/Solution recovered with the 
activated carbon filter  
Fixing solution (SDS-PAGE) 30% (v/v) ethanol/10% (v/v) acetic acid 
Sensitizing solution (Sodium thiosulfate 
solution) 
0.2% (w/v) sodium 
thiosulfate?5H2O/0.5M sodium 
acetate?3H2O/30% (v/v) ethanol/0.5% 
(v/v) glutaraldehyde (25% (w/v) solution) 
Silver nitrate solution 0.1% (w/v) silver nitrate/0.02% (v/v) 
formaldehyde (37% (w/v) solution) 
Developer solution 2.5% (w/v) sodium carbonate pH 
11.3/0.01% (V/V) formaldehyde (37% 
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(w/v) solution) 
Stop solution (Silver staining) 0.05M EDTA pH 8.0 
blocking reagent (PVDF membrane) 5% skim milk/BSA in TBS-T 
 
2.9. SDS-polyacrylamide gel  
2.9.1. Separation gel solution 
Component Volume 
4 – fold separation gel buffer 2.5mL 
Acryl-/Bisacrylamid 8-15% (depending on gel) 
ddH2O ad 10mL 
TEMED 5μL 
10% (w/v) APS solution 50μL 
 
2.9.2. Stacking gel solution  
Component Volume 
4-fold Stacking buffer  1mL 
Acryl-/Bisacrylamid  533?L 
ddH2O 2.46mL 
TEMED 2.4μL 
10% (w/v) APS solution 21μL 
 
2.10. Agarose gel 
1% agarose gel: 0.5g agarose (Eurogentec); 50mL TBE buffer; boil; cool slightly; 5μL 
ethidium bromide (10mg/mL solution). 
 
2.11. Oligonucleotides 
All oligonucleotides for Siglecd1-3-Fc chimera were obtained from the Eurofins MWG 
Operon, Ebersberg, Germany. 
 
Name Sequence (5'?3') Description
OSK695 CGTCTAGAATGCTGCCCCTGCTGCTGCTGCCCCTGC XbaI/ Hu Sig-
5 Sense  
OSK1066 GCAGATCTACTTACCTGTTGAGAGATTCAGAAAAAT BglII/Hu Sig-
5 antisense  
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OSK697 CGTCTAGAATGCTGCTGCTGCTGCTGCTGC XbaI/ Hu Sig-
7 Sense 
OSK1069 GCAGATCTACTTACCTGTGGAGAGGTTCAGGGAAAC BglII/Hu Sig-
7 antisense 
OSK699 CGTCTAGAATGCTGCTGCTGCTGCTGCTGCTGCCC XbaI/ Hu Sig-
8 Sense 
OSK1070 GCAGATCTACTTACCTGTGGAGAGGCTCAGGGAAAT BglII/Hu Sig-
8 antisense 
OSK703 CGTCTAGAATGCTACTGCCACTGCTGCTGTC XbaI/ Hu Sig-
10 Sense 
OSK1071 GCAGATCTACTTACCTGTAGAGAGGTCCAGGGCTCG BglII/Hu Sig-
10 antisense 
 
2.12. Machines and special software 
2.12.1. Centrifuges 
Name Company 
Mini Spin Eppendorf 
Centrifuge 5810 R Eppendorf 
Centrifuge 5804 R Eppendorf 
Optima™LE-80K Ultracentrifuge  Beckman Coulter 
LE-70 Ultracentrifuge  Beckman Coulter 
 
2.12.2. Fluorescence assisted cell-sorting machine 
Name Company 
Coulter·Epics XL-MCL Expo 32 Beckman Coulter 
FLOWCHECK™ Fluorospheres Beckman Coulter 
 
2.12.3. Photometer and flurometer 
Name Company 
MultiScan Acent photometer Thermo Scientific 
MultiScan Acent flurometer Thermo Scientific 
Photometer Fermentas 
Nanodrop Applied biosciences 
ABC real time PCR Applied biosciences 
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2.12.4. Microscope  
Name Company 
Olympus CK2 Olympus 
 
2.12.5. Software 
Name Company 
EXPO 31 ADC Analysis Beckman Coulter 
EXPO 31 ADC XL 3 Color  Beckman Coulter 
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3. Methods 
3.1. Cell culture/tissue culture techniques 
3.1.1. Monocyte Isolation from human buffy-coats or peripheral blood  
In humans, monocytes form approximately 1-10% of total leukocytes and are widely 
used for in vitro generation of macrophages. Several methods for monocyte isolation 
from peripheral blood exist, such as adhesion and negative and positive 
immunoselection. Many protocols for monocyte isolation were devised based on 
density gradient centrifugation (Almeida et al., 2000; Lehner and Holter, 2002). A 
cost-effective method was used to obtain highly enriched, monocyte suspension 
cultures (Repnik et al., 2003). 
 
3.1.1.1. Ficoll density gradient centrifugation 
Human blood samples were obtained from a blood donation unit in Hamburg as 
Buffy-coats or from collected from peripheral vein in the arm of human volunteers. 
Blood was collected into 10mL collection syringe containing citrate buffer to prevent 
coagulation. Blood sample was diluted 1:1 with RPMI media. 35mL of blood 
suspension was overlaid over 15mL of Ficoll solution. Tubes were centrifuged at RT 
(Eppendorf Centrifuge 5810R bench centrifuge) for 15min at 950g 
(acceleration=0/brakes=0). The upper serum layer was carefully transferred into fresh 
falcon tubes in order to prepare autologous serum or CRP analysis. The PBMC layer 
was collected into separate falcon tube, and washed 3 times with 45mL RPMI (350 g/ 
7min /break=3). The cells were stained with Trypan blue and counted using the 
Neubauer-counting chamber. 
 
3.1.1.2. Isolation of monocytes using cell adhesion to plastic surface 
Monocytes were isolated by adhesion to the plastic tissue culture plate surface. 
PBMCs were resuspended in RPMI (10% autologous serum/ Penicillin-Streptomycin) 
and 2-3 million PBMC/well were distributed into 24-well tissue culture plates and 
incubated for 1h at 37°C. After incubation non adherent lymphocytes were removed 
by washing the wells with PBS warmed at 20°C. With this method pure mononuclear 
phagocyte cultures could be obtained. 
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3.1.1.3. Isolation of monocytes by Percoll gradients  
Unattached monocytes in suspension cultures obtained with combined Ficoll/Percoll 
gradient (Repnik, 2003). In the hyper-osmotic percoll gradient, 3mL of the PBMC 
suspension having approximately 50-70 millioncells/mL was then overlaid onto the 
10mL of the hyper-osmotic percoll gradient solution and centrifuged (Eppendorf 
Centrifuge 5810R bench centrifuge) at RT for 15min at 580g (acceleration=0 
/break=0). The monocytes at the interface were collected and washed 3 times with 
45mL RPMI (350g /7min /break=3). After counting, the cells were re-suspended in 
RPMI medium to a density of 50-70 millioncells/mL. 3mL of this monocyte enriched 
suspension was then overlaid on 3mL of iso-osmotic Percolll gradient solution and 
centrifuged (Eppendorf Centrifuge 5810R bench centrifuge) at RT for 15min at 350g 
(acceleration=0 /break=0). The supernatant was discarded and the monocytes pallet 
was re-suspended carefully in less than 1mL of RPMI medium and cells were 
washed 3 times with 45mL RPMI (350g/ 7min/ break=3). Cells were then counted 
before further use. 
 
3.1.1.4. Negative isolation of monocytes from PBMC’s 
Dynal® monocyte negative isolation kit is used for the negative isolation method, 5-
10?107cells/mL PBMC were re-suspended in 0.1% BSA/PBS solution. After adding 
20μL/1?107 PBMC of blocking reagent, cells were incubated for 10min at 4°C. 
Afterwards 20μL antibody mix (provided with the kit) was added per 1?107 PBMC and 
incubated for 10min at 4°C. Cells were centrifuged for 8min at 500g with 1mL of 
PBS/0.1% BSA per 1-5?107 PBMC in Eppendorf Centrifuge 5810R bench centrifuge. 
Cells were then re-suspended in 0.9mL of PBS/ 0.1% BSA/1?107 PBMC. 10μL of 
washed Dynabeads were then added to the cell suspension per 1?107 of cells and 
incubated for 15min at 4°C with gentle tilting and rotation. Rosettes were re-
suspended by pipetting 5-6 times and 1-2mL of PBS/ 0.1% BSA per 1?107 PBMC 
was added. The tube was placed in the Dynal MPC magnet for 2min and monocytes 
containing supernatant were transferred to a fresh tube. The cells were counted 
before further use. 
 
3.1.2. Cell counting: Neubauer counting chamber 
Cells were counted using the Neubauer counting chamber. Staining with trypan blue 
ensures that the total number of viable cells in a cell suspension can be counted as 
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trypan blue stains the dead cells with its characteristic blue colour. Such cells are 
therefore not included during counting. Cells were mixed in 1:1 proportion with 2? 
Trypan-blue solution and 10μL was applied to a Neubauer counting chamber. The 
total number of cells in one of the big nine squares of the Neubauer chamber was 
counted under phase contrast microscope. At least three large squares were counted 
and average numbers used in calculating the total number of cells. The number of 
cells per/mL was obtained by multiplying the average cell count in the large squares 
with 104. 
 
3.1.3. Human monocytes and monocyte-derived macrophage culture 
Macrophages can be obtained by culturing monocytes for 4-6 days in the presence of 
2ng/mL recombinant human M-CSF (Gordon, 1995; Montaner et al., 1994; Montaner 
et al., 1999). Monocyte and monocyte-derived macrophage cells were cultured in 
either special high binding plates (SARSSTED-24 or 6 well plates) or maintained in 
suspension culture (6 well CORNIG plates). Cells were maintained in RPMI/ 2.5% 
autologous serum/ Penicillin-Streptomycin. 
 
3.1.3.1. Activation of monocytes and monocyte-derived macrophages  
Mononuclear phagocytes can be pre-activated by adding 20ng/mL recombinant 
human IL-4 overnight. For IFN? activation cells were primed initially for 4h with 1 
U/mL recombinant human IFN? followed by overnight incubation in the presence of 
100 U/mL recombinant human IFN?, under 5% CO2 in H2O saturated atmosphere at 
37°C. 
 
3.1.4. Cultivation of FRhK-4 cells 
FRhK-4 cells were maintained in DMEM medium (DMEM/ 10% heat-inactivated FCS/ 
Penicillin-Streptomycin /L-glutamine) under 5% CO2 in H2O saturated atmosphere at 
37°C. The cells were grown to 90% confluency before passaging onto fresh tissue 
culture flasks.  
 
3.1.5. Virus cultivation and purification 
3.1.5.1. HAV-7/ Coxsackie B virus cultivation and purification 
FRhK-4 cells were infected with 1mL of seeding supernatant containing HAV-7 or 
Coxsackie B2 virus and incubated at 37°C for 14 days. Infected cells with medium 
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were freeze-thawed three times. Cell debris was removed by centrifugation at 2000 
rpm for 15 min. The supernatant was transferred to 50mL falcon tubes and 50mM 
Tris-HCl (pH 7.5)/ 10mM MgCl2/ DNaseI 20μg/mL was added and incubated at 37°C 
for 30min. The following detergents (0.4% DOC, 1% NP-40/ 0.5% Sarcosine/ 50mM 
EDTA) were then added and incubated for 1h at RT (Approx. 20mL of this solution 
was dispensed per 50mL falcon tube). DNA was removed by adding an equal volume 
of chloroform to the cell culture supernatant at 4°C for 30 min. The tubes were 
centrifuged for 20min at 2500 rpm. Chloroform extraction step was repeated for 
approx. 3 times until clear inter-phase was obtained. Trace amounts of chloroform 
were removed from aqueous phase by vacuum-drying for 1h.  
Sucrose gradient centrifugation was performed on the aqueous phase with 0.4% 
DOC/40% sucrose/0.5% Sarcosine/1mM Tris-HCl (pH 7.5)/ 100mM NaCl/ 50mM 
EDTA (pH 8.0)/ 1% NP-40 gradient solution. The supernatant was removed with a 
pipette without disturbing the pellet. Pellet was resuspended in 1mL PBS and 20μL 
aliquots were stored at -80°C in sterile reaction cups. 
 
3.1.5.2. Determination of tissue culture infectious dose50 
FRhK-4 cells were diluted 1:8 using DMEM/ 1% FCS and distributed in two 96 well 
flat bottom micro titre plates. 10-2 to 10-12 viral dilutions were prepared in DMEM/ 1% 
FCS. 100μL of diluted viral sample was distributed in respective wells and plates 
were incubated at 37°C at 5% CO2 for approximately 7 days. The plates were 
observed under light microscope to determine the cytopathic activity (Coxsackie B2 
virus) or after 14 day incubation immunocytochemistry assay was performed for 
HAV-7 virus. Tissue culture infectious dose50 (TCID50) was calculated using 
equation developed by KÄRBER formula (Spearman et al, 1908, Karber et al., 1931). 
 
3.1.5.3. Cultivation and purification of influenza virus strain A/PR8/34 
Propagation of influenza virus was carried out in pathogen-free chicken eggs after 
11-12 days of fertilization. The egg was placed in front of a light source to locate a 
non-veined area of the allantoic cavity just below the air sac, which was marked with 
a pencil. After sterilization with 70% ethanol, a small nick was made in the shell using 
a jeweler’s scribe. Next, a hole was drilled at the top of the egg. The allantoic cavity 
of the egg was inoculated with the virus using a 1mL tuberculin syringe fitted with a 
1/2 inch, 27gauge needle. The two holes in the shell were sealed with parafilm. The 
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eggs were then incubated for 2 to 3 days in temperature and humidity controlled 
incubators so as to effect viral infection under optimal conditions. Incubation was 
stopped by rapid refrigeration at 5 ±3°C. The virus was harvested by removing the 
part covering the air sac on the top of the egg shell. The shell membrane and 
chorioallantoic membrane were pierced with a pipette which was then used to 
remove about 10mL allantoic fluid per egg. The allantoic fluid containing virus was 
centrifuged at 3000 rpm, for 1h at 4°C. After this step, 1.04 - 1.16 g/mL of cleared 
allantonic fluid was then placed on the top of a sucrose gradient (for sucrose cushion 
Optima™LE-80K Ultracentrifuge with, SW20 Ti Rotor, 15,000 rpm 1h and then 
40,000 rpm overnight). The supernatant was removed with a pipette without 
disturbing the pellet. Pellet was resuspended in 1mL PBS and 20μL aliquots were 
stored at -80°C in sterile reaction cups. 
 
3.1.6. Maintenance of K562 human chronic myeloid leukaemia cells 
K562 cells were cultured in H2O saturated atmosphere at 37°C under 5% CO2 
condition in RPMI (RPMI/ 10% heat-inactivated FCS) medium. For passaging, 3 fresh 
culture dishes were made from a single plate that was grown to 90% confluence. 
 
3.1.6.1. Co-culture of human mononuclear phagocyte with K562 tumour cell 
or viruses 
For co-culture experiments K562 cells grown to 70% confluent were harvested and 
with 45mL RPMI (350g/ 7min/ break=3) and added to the mononuclear phagocytes in 
1:5 ratios. Cells were incubated in RPMI cell culture media from 30min to 20h at 
37°C at 5% CO2. K562 erythrolukemia cells were either kept untreated or AUS-
treatmetn was carried out before added to co-culture system. In the same manner 
K562 membrane preparations were also co-cultured with mononuclear phagocytes. 
In some experiments, mononuclear phagocytes were pre-activated with the typical 
Type-I or Type-II T-helper cell cytokines (IFN? and IL-4). For inhibition of Sia 
mediated activation of mononuclear phagocyte experiments anti siglec antibody was 
added 1h before adding K562 cells to co-culture system. 
For cytokine analysis co-culture supernatant was then collected and centrifuged 
down for 2min at 2000rpm at RT. After changing the reaction tube supernatant was 
again centrifuged for 15min at 14000 rpm at 4°C and stored immediately at -80°C 
until further use.  
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To monitor changes in monocyte surface limited siglec expression, monocytes in 
suspension culture were co-cultured with either enveloped viruses (Influenza virus, 
NDV, CMV) or non-enveloped viruses (HAV-7, HAV-GBM, viruses) in RPMI cell 
culture media from 10min to 20h at 37°C at 5% CO2. In case of Influenza and 
Coxsackie B2 virus co-culture experiments (10μL of undiluted sample) and for NDV, 
CMV, HAV-7 and HAV-GBM (100μL of undiluted sample) were directly added to 
monocytes. Three different dilutions (1:100, 1:1000, and 1:10000) were also tested 
for time verses virus concentration experiments. 
 
3.1.7. Development of chemically competent bacteria cells 
?DH5 and XL1-blue strains of Escherichia coli were made competent by the 
chemical method. A 1mL overnight starter culture of the desired E. coli strain was 
added to 100mL of preheated LB medium containing 2mL of 1M Mg2+ solution. The 
culture was incubated at 37°C on a shaker at 240rpm. At regular intervals the optical 
density of the culture was measured at a wavelength of 600nm until a value of 0.5 
OD was attained. The culture was centrifuged for 10min in 50mL tubes at 4000rpm at 
4°C (Eppendorf table centrifuge 5810). The supernatant was discarded by decanting 
the tube. Cell pellets were resuspended in 25mL TMF buffer and kept on ice for 1h. 
The cells were again centrifuged and resuspended in 5mL fresh TMF buffer plus 1mL 
of glycerol. 200?L aliquots in 1.5mL reaction tubes were prepared and immediately 
stored at -80°C. 
 
3.1.7.1. Transformation of chemically competent bacteria 
The heat- shock treatment or method was used to achieve transformation of bacteria 
cells. For this, a 200μL aliquot of frozen competent cells was thawed and 50μL of 
ligation mixture was added. The reaction mixture was shaken gently and incubated 
for 30min on ice. Subsequently, the bacteria were placed in a water bath (heat shock) 
for 2min at the 42°C, chilled briefly on ice and 700 ?L of SOC medium was added 
immediately and incubated in a shaker for 45min at 37°C and 240 rpm. The bacterial 
suspensions were centrifuged for 1min at 1000rpm and the supernatant was 
removed. The pellet was resuspended in 100μL SOC medium, and then spread on a 
LB/Amp agar plate and incubated at 37°C overnight.  
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3.1.8. Production of stable cell lines 
3.1.8.1. Cultivation and maintenance of adherent eukaryotic cells  
CHO-K1/Lec1 cells were grown in ?-MEM medium with 10% heat-inactivated FCS. 
Incubation was at 37°C under 5% CO2 in H2O saturated atmosphere. The cells were 
grown to 90% confluency before they were passaged onto several 10cm cell culture 
dishes. For passaging, the following steps were carried out. Cell culture dishes were 
washed 2? with 7mL 1?PBS and then 1mL trypsin-EDTA solution (per 10cm plate) 
was added to the cells. The solution was immediately aspirated and the cell culture 
dishes were incubated for 2-5min in the incubator. The detached cells were 
resuspended in 10mL culture medium and evenly distributed on the cell culture 
dishes. 
 
3.1.8.1.1. FCS Immunoglobulin-depletion 
To avoid contamination of secreted siglec Fc chimeras with immunoglobulin from 
FCS that is contained in the cell culture media, 20% FCS in the culture medium 
(RPMI or DMEM) was incubated overnight at 4°C with protein A-sepharose beads 
(GE Healthcare). The immunoglobulin Fc part binds to Protein A and thus Ig’s can be 
removed (Bebbington, 1991). Protein A beads were removed by passing the media 
over a column with membrane and then a sterile filter before storing at -20°C.  
 
3.1.8.2. Stable transfection of CHOLec1 cells  
The pDEF vector in which Siglecd1-3 coding sequences was inserted contained -(3c)-
Fc, in addition to the ampicillin resistance gene, the hygromycin B resistance gene 
which could be used as marker in selecting stable cell lines. Only successful 
transfected CHO cells could survive the antibiotic hygromycin B because of the 
hygromycin B phospho-transferase (HygR) resistance activity impacted upon them 
from the pDEF vector upon successful uptake of the plasmid. For stable transfection 
cells were cultured in ?MEM with 10% FCS until they were 70-80% confluent. The 
cell culture medium was removed and the cells were washed once with PBS. 
Transfection was carried out with the cationic polymer ExGen500 (MBI Fermentas) 
according to the protocol provided by the manufacturer. This reagent forms 
complexes with the DNA which are then deposited by gravity on the cells and are 
absorbed probably by endocytosis from the cell. For confluent cells on a 100mM cell 
culture dish, 58μg of DNA was added to an appropriate volume of sterile 150mM 
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NaCl solution and was mixed gently and centrifuged briefly. Then 192μL ExGen500 
was added, bringing the total volume to 1mL, mixed by vortexing for 10 sec and then 
incubated for 10min at RT. The transfection mix was added to a cell culture dish filled 
with 14mL serum-free ?MEM medium. After 3-4h old culture medium was removed 
and replaced with fresh 20mL pen/strep containing cell culture medium. 
 
3.1.8.3. Selection of stably transfected cells 
The cells were trypsinized and resuspended in 5mL medium after a 24h incubation 
period. To determine the cell density, cells were counted with Neubauer-counting 
chamber. The cell density was adjusted to 5?105cells/mL. For selection of 
successfully transfected cells, hygromycin B was added in different dosages starting 
with at least 350 g/mL concentration. The outer rows were filled with copper sulphate 
solution to prevent contamination. After 3-5 days, plates were checked under phase 
contrast microscope to ascertain degree of cell survival. Media was changed on a 
weekly basis. After 2-3 weeks the hygromycin-resistant cell populations were 
screened for production and secretion of siglecs by sandwich ELISA. Highest 
producing cells were selected and transferred to 6-well culture plates. Subsequently 
they were transferred to 10cm culture plates. 
 
3.1.8.4. Recombinant Fc-chimeras production 
Successful expression of siglec Fc-chimeras was determined by sandwich ELISA. 
Recombinant Fc-chimeras was harvested every 2 or 3 days, cells in suspension 
culture were centrifuged for 7min at 700 rpm to harvest the supernatant. Cells were 
resuspended in fresh medium and were further incubated. The pH of the harvested 
supernatant was adjusted with 1M HEPES, and centrifuged for 20min at 9000 rpm 
(Eppendorf Centrifuge 5810R bench centrifuge) to remove any cell debris. The 
supernatant was then sterile filtered (0.2μM) to remove any contaminants and then 
stored at -20°C until purification. 
 
3.1.8.5. Adaption of CHOLec1 cells to EX-CELL® Chemically defined CHO 
Serum-free media 
EX-CELL® Chemically defined Hydrolysate Fusion media is an animal product free, 
chemically defined media. This synthetic media is specially optimized for Chinese 
Hamster Ovary (CHO) cell lines. Cells grown in this media do not adhere but rather 
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are in suspension. To avoid immunoglobulin contamination from FCS and to increase 
the production of siglecs, cells were adapted for EX-CELL® CD CHO serum free 
medium. Culture supernatant was harvested every other day and pH was adjusted 
with 1M HEPES. Supernatant was centrifuged for 10min at 900rpm to remove dead 
cells and other debris.  
 
3.1.9. K562 membrane protein preparation 
K562 cells were pelleted at 300g and washed twice in Dulbecco's PBS (DPBS) and 
then resuspended in a cold solution containing 100mM KCl, 5mM NaCl, 3mM MgCl2, 
50mM Hepes, pH 7.4, and 1mM dithiothreitol (DTT) (lysis buffer) and placed on ice 
for 20 min. The suspension was centrifuged at 500g and 4°C for 10 min, to remove 
nuclei and unbroken cells, and the supernatant then spun at 14000g and 4°C for 10 
min. The resulting pellet was resuspended in lysis buffer containing 1mM EGTA and 
then homogenized in a Teflon-glass homogenizer with 10 strokes of the pestle. 
Following a further spin at 14000g and 4°C for 10 min, the crude membrane fractions 
were resuspended in 50mM Tris/HCl, pH 7.0, at approx. 2mg/ml and stored at -80°C 
till use. Protein determinations were by the BSA assay method using BSA as 
standard. 
 
3.2. Assays 
3.2.1. Flow cytometry analysis 
Flow cytometry analysis of a single cell suspension yields multi-parameter data 
corresponding to Forward Light Scatter (FSC), 90° Light Scatter- Side scatter (SSC), 
and FL1-FL4. This information allows identifying and characterizing various 
subpopulations of cells. Scattered and emitted light from cells is converted to 
electrical pulses by optical detectors. The electrical pulses generated from light are 
then processed by a series of linear and log amplifiers. Logarithmic amplification is 
most often used to measure fluorescence in cells. The instrument used here was the 
Beckman-Coulter XL instrument, bench-top flow cytometer analyzers (COULTER® 
EPICS®XL™).  
With flow cytometry the expression levels of distinct cells surface structures can be 
analyzed. Fluorescent labelled antibodies used to measure cell surface expression of 
distinct proteins and polyvalent oligosaccharides probes to analyse the presence of 
corresponding glycane structures on the cells.  
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For staining, approx 100000–200000 cells were liquated per well in 96 well round 
bottom micro titter plates in 100μL staining buffer. Staining was achieved by 
incubating cells first with the primary reagent (i.e. specific antibodies, or sugar 
probes) for 6h or overnight at 4°C. After washing the cells 3? with 200μL staining 
buffer, the fluorescent labelled secondary detection reagent was added and cells 
were incubated for 4h at 4°C. Cells were washed and fixed by adding 150μL 0.08% 
paraformaldehyde (PFA) in staining buffer. Flow cytometry analysis was then 
performed. 
 
3.2.1.1. Binding of siglec-Fc chimera to K562 cells 
1-2x105 untreated or sidalidase-treated K562 tumour cells were resuspended in 
100μL staining buffer (10mg/mL BSA, 10mM PBS pH 7.4, 0.01% NaN3). Incubated 
with 2μg of Siglec-Fc chimeras (Siglec-1, -3, -5, -7, -8, -9, -10 either purified from 
CHOK1 or Lec1 cells) for 1h on ice. Cells were washed 3? with 350μL of staining 
buffer and either fixed directly with 0.8% paraformaldehyde in PBS and stained for 
another hour on ice with the 2μL PE-labelled anti hu-IgG-Fc antibodies prior to 
additional washing and fixation. Flow cytometry data were acquired using a flow 
cytometer. 
 
3.2.1.2. Determination of PAA-biotin glycan binding 
1x105 cells were resuspended in 100μL staining buffer (10mg/mL BSA, 10mM PBS 
pH 7.4, 0.01% NaN3) and incubated with 1μg PAA-biotin glycan probes for 1h on ice. 
Cells were washed twice with 1mL of staining buffer and either fixed directly with 
0.8% paraformaldehyde in PBS and stained for another hour on ice with the PE-
streptavidin prior to additional washing and fixation. Flow cytometry data were 
acquired using a flow cytometer. 
 
3.2.1.3. Detection of monocytes from PBMC’s 
1-2x105 PBMC’s were resuspended in 100μL staining buffer and 8μL of fluorescent 
labelled (FITC) anti CD14 antibody was added to the sample and incubated for 6h at 
4°C. After washing the cells 3? with 350μL FACS buffer and fixed directly with 0.8% 
paraformaldehyde in PBS, cells were analysed by flow cytometer. 
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3.2.1.4. Siglec detection on monocytes 
1-2x105 monocyte enriched sample or monocyte-virus co-culture samples were 
resuspended in 100μL staining buffer, and 1-5μL monoclonal mouse anti hu-Siglec 
antibodies was added to the sample and incubated for 6h-20h at 4°C. After washing 
the cells 3? with 350μL FACS buffer and fixed directly with 0.8% paraformaldehyde in 
PBS, 2μL PE-labelled anti mouse IgG Fc antibodies was added for another 4h on ice 
to detect siglec expression by flow cytometer. 
 
3.2.2. Enzyme-linked immunoadsorbent assay (ELISA) 
3.2.2.1. Human Interleukin-6 and -1? ELISA 
The ELISA performed was the two-step sandwich ELISA. Released pro-inflammatory 
cytokines from monocyte-K562 tumour cell co-culture supernatants were analysed 
using an ELISA kit. Microwells were filled with 100?L of IL-6 or IL1? capture antibody 
diluted in bicarbonate coating buffer. Plates were sealed with parafilm and incubated 
overnight at 4°C. On the following day, wells were aspirated and washed 3? with 
~300?L /well wash buffer consisting of 2% FCS. To avoid unspecific binding, plates 
were blocked with ~200μL/well assay buffer. Incubation was carried out at RT for 1h. 
Then, the plates were aspirated and washed with ~300?L /well with wash buffer. 
100?L of each standard, sample, and control were pipetted into appropriate wells and 
after sealing with parafilm incubated for 2h at RT. Wells were washed 5 times with 
~300?L wash buffer /well and 100?L of working detector solution (Detection Antibody 
+ SAv-HRP reagent) was added to each well. The sealed plate was incubated for 1h 
at RT and washed 7 times with ~300?L /well wash buffer (in this final wash step, 
soak wells in wash buffer for 30 sec for each wash). 100?L of substrate solution was 
added to each well and the plate was incubated without plate sealer for 30min at RT 
in the dark. 50?L of stop solution was added to each well before reading the 
absorbance at 450nm after 30min of stopping reaction. 
 
3.2.2.2. Quantitative sandwich ELISA for detection of produced Fc chimeras 
Purified proteins or cell culture supernatants of Siglec-Fc chimeras were detected in 
a sandwich ELISA with antibodies against the human Fc portion. The micro titter 
plate was coated at 4°C overnight with 10μL of anti-human IgG solution (capture 
antibody) in bicarbonate buffer. Next day, the capture antibody solution was 
 Methods 34 
discarded by flipping the plate on paper towels and the plate was washed 3 times 
with TBS/Tween20 solution. Then 5μL of an anti-human IgG-AP solution mixed with 
5?L of Siglec-Fc solution in a 1:2 dilution series was added. For calibration 1:5 serial 
dilution series in TBS/Tween20 starting from 2μg/mL of only Fc-part was used. 
TBS/Tween20 was used as a negative control. The cell culture supernatants from 
stable cell lines grown in Excel media were previously diluted at least 1:10 before a 
1:2 dilution series was made. For each dilution of the Fc-chimera, triplicate 
determinations were performed. The Fc chimeras/anti-human IgG-AP (secondary 
antibody) mix were applied and incubated for 4h at 4°C to allow the Fc part to bind to 
the immobilized antibody. After incubation, the supernatant was discarded and the 
plate was washed 3? with TBS/Tween20. By adding an enzyme substrate, in this 
case 20?L FDP solution, Fc-chimeras concentration can be determined. The signal 
was quantified by a Fluroscan Ascent (Thermo Life Sciences) fluorescence plate 
reader at Ex/Em = 485 ±20 / 528 ±20nm. The concentration of the samples was 
calculated using the established calibration curve. 
 
3.2.2.3. Solid phase cell binding assay  
The Sia-specific binding of Siglec-Fc chimeras was verified by a solid phase assay 
with human erythrocytes as target cells whose surfaces glycans carry ?2,3- and ?2,6-
linkages for Sia. Blood was obtained from a volunteer donor with a serum collection 
syringe which contained citrate as anticoagulant. The blood was centrifuged for 
10min at 2000rpm in an Eppendorf 5810R bench centrifuge. The plasma and the 
leucocytes were removed by suction, the red cell pellet was washed 3? with HBS and 
resuspended in AoAB (Alsevier's Buffer) and stored at 4°C. Buffer was changed on a 
daily basis. 
As a control for nonspecific, non-Sia-dependent binding sialidase treated 
erythrocytes were used; the Sias were removed with sialidase enzyme from Vibrio 
cholerae (VCS). The solid phase assay was performed similarly to the sandwich 
ELISA (instead of secondary antibody, human erythrocytes were used). Captured 
Siglec-Fc chimeras were incubated with 50μL of the 0.5% solution of erythrocyte 
suspension in HBA. Cells were incubated for 1h at RT. Unbound erythrocytes were 
resuspended by gently shaking the plate and removed by aspiration. The bound 
erythrocytes were fixed by adding 100?L 0.25% glutaraldehyde solution in HBS with 
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gentle shaking of the plate. After fixation, the wells were washed twice with HBA and 
cell-formations observed under the microscope. 
 
3.2.2.4. C-reactive protein (CRP) assay  
The assay is based on the double antibody sandwich format where bound anti-CRP 
antibodies capture CRP from serum. This bound CRP can be detected with an 
enzyme that conjugates anti-CRP antibody after adding chromogenic enzyme 
substrate to the wells. This reaction is stopped with EDTA and the optical density 
measured to reveal levels of CRP. CRP concentrations are read off the standard 
curve and, when corrected by the dilution factor, give the CRP concentration in the 
serum sample. 
Samples and standards were prepared to an appropriate dilution for each specimen 
to be tested according to the manufacturers’ instructions. 50?L of each CRP standard 
and diluted test sample was dispensed into designated microwells. Then they were 
mixed briefly on a plate shaker, covered, and incubated at RT for 60min. After 
washing the micro tittre wells with 350?L of working-strength wash solution, 100?L 
CRP Tracer solution was added and mixed briefly before incubated for 60min at RT. 
After washing, 100μL of substrate solution was added and incubated uncovered at 
RT for 30min. To stop the reaction 100μL EDTA solutions was added and the OD 
was measured at 405nm in MultiScan Acent Photometer.  
 
3.2.3. BCA (bicinchoninic acid) protein assay 
With the help of the BCA protein test based on bicinchoninic acid, the amount of 
protein in solution was measured (BCA™ ProteinAssayKit, Pierce). For calibration, 
BSA concentration standards ranging from 0.025-2.0mg/mL were used. 5?L protein 
solution was pipetted into the micro titter plate wells in duplicate. 100?L of the 
reaction mixture from the BCA kit was then added and briefly mixed; the micro titter 
plate was then covered with parafilm layer and incubated for 30min at 37°C. After 
incubation, the OD was measured at 562nm in a Multiscan Ascent (Thermo Life 
Sciences) photometer. Using the BSA calibration series, the protein concentration 
was determined for each sample. 
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3.2.4. Immunocytochemistry of monocytes and K562 tumour cells 
Monocytes were allowed to adhere in 24-well plates before tumour cells were added 
to the cultures, and then they were co-cultured for 6-18h. After co-culture, cells were 
washed carefully twice with PBS followed by fixation of the cells for 10min using 4% 
paraformaldehyde in PBS. Fixed cells were washed twice with PBS and the 
remaining free aldehyde groups were blocked by incubation with PBS/10% FCS for 
1h at RT. Free Fc-receptors of monocytes were then blocked for 30min by adding 
10μg/mL purified human Fc-fragments diluted in PBS/3% bovine serum albumin 
(BSA). Cells were then stained with mAb antiSiglec-7 hybridoma cell culture 
supernatants diluted 1:5 in PBS/3% BSA, followed by detection of bound antibodies 
using TRITC-labelled anti mouse IgG antibodies. 
 
3.3. Protein biochemistry 
3.3.1. Ultracentrifugation of cells culture supernatant  
The cell culture supernatant was thawed and sodium azide solution was added 
(0.02% (v/v)) to prevent any bacterial contamination. Approximately 65mL of 
supernatant was dispensed in each ultracentrifuge tube and the tubes were carefully 
balanced to a difference of not more than 0.05g, as recommended by the 
manufacturer of the instrument (Beckmann Coulter). Ultracentrifugation was carried 
out at 4°C at initially at 7800rpm for 15min and then at 40000rpm for 45min in TI-45 
rotor (Beckmann Coulter). The supernatant was taken out carefully without disturbing 
the pellet. 500μL aliquot was taken from supernatant for SDS-PAGE, ELISA and was 
stored at -20°C. 
 
3.3.2. Purification of Fc chimeras and antibodies using Protein A beads  
Purification of antibody/Siglec-Fc chimera was carried out at 4°C. 1mL Protein A 
beads were equilibrated with Wash buffer I (WB I). The equilibrated beads were 
added to the cell culture supernatant and incubated overnight at 4°C (batch process) 
on a rotary shaker. The following day, beads treated supernatant was passed over 
column with membrane in order to retain protein A-Sepharose beads for elution of 
bound protein. Beads were first washed with 100mL WB I and then with 100mL Wash 
buffer II (WB II). The elution from beads was done by pH shock by applying 500μL 
Elution buffer I (EB I). Every time, 15-20 samples were collected in 1.5mL reaction 
tube. To prevent conformational changes of the protein due to the pH shock, 
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neutralization of the eluted samples was done immediately by adding 75μL 
Neutralization buffer (NB). The cups were vortexed immediately for better mixing. 
Protein A beads were regenerated using 20mL elution buffer II followed by 5mL NB. 
Washing was done by 20mL WB II and column was stored in 20mL 20% ethanol in 
WB II. Absorbance of all the fractions was measured by a photometer. Fractions with 
O.D at 280 that were > 0.05 were pooled together. Sodium azide was added to a final 
concentration of 0.02% and the reaction cups were kept for 30min at 4°C.  
 
3.3.3. Buffer exchange using PD-10 column 
Buffer exchange was carried out by gel permeation chromatography using PD-10 
column (Sephadex 25, GE Healthcare) against 1? HBS. The column was cleaned 
with 2 column volumes of ddH2O followed by 2 column volumes 0.1M NaOH/1% 
SDS, then with 2 column volumes of 0.1M HCl and with 2 column volumes of double 
distilled water. The PD-10 columns used here accommodated a maximum volume of 
2mL. Therefore, larger protein volumes were concentrated using Vivaspin 6. 2mL 
sample was loaded and elution was done with 1? HBS. 30 fractions of 500μL each 
were collected. Absorbance was measured and fractions with O.D at 280 of 0.05 
were pooled. Sterile filtration was done using Vectaspin Micro, 0.2 μm. Centrifugation 
was done for 2min at 2000rpm. The final protein content was determined by BCA 
assay. All the aliquots were stored at 4°C. 
 
3.3.4. Quality control and characterization of purified proteins 
3.3.4.1. SDS-polyacrylamide gel electrophoresis 
SDS-PAGE was performed in mini gel apparatus from BIO-RAD (Hercules, 
California, USA) with the buffer system (Tris-glycine-HCl) according to Laemmli 
(Laemmli, 1970) under denaturing and non-denaturing conditions. 
The protein samples were prepared by adding an equal volume of 2-fold 
reducing/non-reducing sample buffer before boiling for 5min at 95°C. The mini gels 
were loaded with the denatured proteins and with a molecular weight standard and 
electrophoresis was performed at 15mA/gel for approximately 1-1.5h. For western 
blotting pre-stained protein standards were used. 
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3.3.4.2. Coomassie brilliant blue staining 
The proteins in the SDS PAGE gel can be visualized with Comassie Brilliant Blue 
G250 (SERVA Blue R; SERVA, Heidelberg), triphenyl methane dye. After washing 
the separation gel with ddH2O in order to remove SDS, it was incubated for 30-50min 
in Coomassie Brilliant Blue solution. The separation gel was washed briefly in ddH2O 
before gradually distained with distaining solution. 
In later experiments Coomassie-based protein staining solution PageBlue? from MBI 
Fermentas was used. PageBlue? solution has a higher sensitivity and contains no 
methanol and can be decolorized with ddH2O. 
 
3.3.4.3. Silver staining 
SDS-gels are fixed with 50mL fixing solution. Then 50mL of sensitising sodium 
thiosulfate solution was added and incubated for 30min. After washing gels 3? in 
ddH2O for 20min, 50mL of silver nitrate solution was added and incubated for 30min. 
The gels were washed three times quickly with ddH2O. To visualize the protein 50mL 
of developer solution was added. If the developer solution turned brown, fresh 
developer solution was added till we observed clear protein bands. To stop the 
reaction 50mL stop solution was added and incubation was performed for 15min. 
Before handling gels were rinsed with ddH2O. 
 
3.3.4.4. Western Blotting 
The transfer of proteins from electrophoresis gels to an immobilizing membrane is 
called the protein or Western blotting (Towbin et al., 1979).Here, the protein transfer 
took place under an electric field (Kyhse-Andersen, 1984) in a blotting chamber (Mini 
Trans-Blot? Electrophoretic Transfer chamber, to a polyvinylidene difluoride 
membrane (PVDF membrane). The PVDF membrane was first soaked in 100% 
methanol and then dampened in ddH2O, before it was put in the threshing cassettes 
together with gel and all other components in blotting buffer. According to the 
manufacturer’s instructions the components were placed together in the gel cassettes 
without any air bubbles because it may interfere with blotting process. The transfer 
took place in the chamber filled with Blotting buffer with a constant 100V for 1h at 4° 
C. After successful transfer the pre-coloured (pre-stained) protein standard will be 
visible on the membrane, the gel side of the PVDF membrane was marked and the 
membrane was washed for 10min in TBS-T buffer. 
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3.3.4.4.1. Immunodetection of proteins 
For the immunodetection of proteins on PVDF membrane, membrane was incubated 
overnight at 4°C in blocking reagent. The membrane was washed five times for 5min 
in TBS-T buffer. The primary antibody solutions were pipetted onto the protein side 
on membrane and incubated for 1-1.5h at RT. After washing the membrane as 
described before, it was placed in 20mL of the secondary peroxidase (POD)-
conjugated antibody containing solution and incubated for 1h at RT under slightly 
shaking conditions. The detection was carried out with the ECL (Enhanced 
Chemoluminescence) reagent. 1mL substrate solution was prepared according to the 
manufacturer instructions and membrane was incubated on parafilm for 5min. 
Membrane was exposed with an X-ray film for 0.5 to 10min and then the exposed film 
was developed in an Agfa Curix60 film developer; the machine was set according to 
manufacturer's instructions.  
 
3.4. Sialidase treatment 
3.4.1. Vibrio cholerae sialidase treatment 
The enzyme sialidase from Vibrio cholerae (VCS) removes Sias from protein surface. 
For the VCS-treatment 190μL packed (previously centrifuged) human erythrocytes 
were washed three times with HBA with 2mM CaCl2, and then in 310μL calcium-HBA 
(HBA/2mM CaCl2) then 40mU/mL (40μL) VCS was added and incubated for 3h at 
37°C. After incubation, the cells were washed five times with three times more 
volume of HBA and finally resuspended for storage in AoAB. 
 
3.4.2. Arthrobacter ureafaciens sialidase treatement  
To remove Sia from cell surface under mild physiological conditions, 1-6x106 cells 
were washed twice with 1mL RPMI/50mM HEPES pH 6.9, resuspended in 1mL 
RPMI/ 50mM HEPES pH 6.9 containing 20mU Arthrobacter ureafaciens sialidase 
(AUS), incubated at RT for 30min and washed 5 times with the buffer used in the 
following steps. 
 
3.5. Molecular biology methods 
3.5.1. Human Interleukin-6 real time polymerase chain reaction (TaqMan) 
Real-time polymerase chain reaction (RT-PCR) enables both detection and 
quantification of one or more specific sequences in a DNA sample as absolute 
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number of copies or relative amount when normalized to DNA input or additional 
normalizing genes. To perform RT-PCR, total RNA was isolated from mononuclear 
phagocytes and after DNase treatment to remove contamination DNA (Promega 
DNAse) RNA concentration in each sample was quantified. RNA was then reversely 
transcribed to make cDNA and then PCR was performed to quantify IL-6 mRNA copy 
number with calibrated sample. 
 
3.5.1.1. peqGOLD Isolation Systems TriFast™ 
Total RNA from mononuclear phagocytes after co-culture with K562 cells was 
extracted, by using peqGOLD Isolation Systems with TriFast™ solution from PEQLAB 
Biotechnologie GmbH. Cells were directly lysed in culture dish by addition of 
TriFast? and by passing the cell lysate several times through a pipette. The amount 
of TriFast? needed is based on the area of the culture dish (1mL per 10cm2) and not 
on the number of cells. 0.2mL of chloroform was added and incubated for 15sec and 
reagent tubes were shaken vigorously by hand and again incubated for 3-10min at 
RT. After centrifugation at 12000g the RNA containing aqueous phase was collected 
in fresh reaction tube. The RNA was precipitated with 0.5mL of isopropanol per 1mL 
of Tri-Fast? samples by centrifuge for 10min at 4°C at 12.000g max. The RNA pellet 
from bottom was carefully collected and washed twice with 75% ethanol by vortexing 
and subsequent centrifugation for 8min at 7500g at 4°C. The excess isopropanol 
from the RNA pellet was air-dried and the RNA pellet was resuspended in Rnase-free 
water before storing at -20°C until further use. Aliquote was taken to check RNA 
quantity and quality with photometer. 
 
3.5.1.2. Preparation of DNA-free RNA 
DNaseI is an endonuclease that digests single- and double-stranded DNA. The 
enzyme activity is strictly dependent on Ca2+ and is activated by Mg2+ or Mn2+ ions. 
To an RNase-free tube 1μg total RNA was added with 1μL 10? reaction buffer with 
MgCl2, 1μL (1U) DNaseI, and filled up to 10μL with DEPC-treated Water, incubated 
at 37°C for 30min. To deactivate DNase activity, 1μL 50mM EDTA was added and 
incubated at 65°C for 10min. This RNA preparation was used as a template for 
reverse transcriptase. 
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3.5.1.3. cDNA Synthesis for RT-PCR 
RevertAid™ Hminus Reverse Transcriptase (RT) is a genetically modified M-MuLV 
RT. The enzyme possesses RNA-dependent and DNA dependent polymerase 
activity, but lacks RNase H activity due to point mutation in the RNase H domain. To 
generate first-strand cDNA for use in two-step RT-PCR, 100ng of total RNA in a 
sterile, nuclease-free tube was mixed with Oligo(dT)18 primers, filled up to 12.5μL 
with DEPC-treated water, mixed, briefly centrifuged and incubated at 65°C for 5min, 
chilled on ice, again briefly centrifuged and placed on ice. 4μL of 5? Reaction Buffer, 
0.5μL (20U) RiboLock™ RNase Inhibitor, 2μL (1mM final concentration) dNTP 
(10mM) Mix, and 1μL (200U) RevertAid™ Hminus Reverse Transcriptase was added 
to this solution to obtain a total volume of 20μL. The reaction tube was gently shaken 
and centrifuged briefly before being incubated for 60min at 42°C. The reaction was 
terminated by heating at 70°C for 10min. The reverse transcription reaction product 
was then stored at -20°C. 2μL aliquot of the reaction mix was taken to perform 
control PCR with Tubuline primers. 
 
3.5.1.4. TaqMan® IL-6 real time PCR 
To quantify the expression of human IL-6, commercial TaqMan® Pre-Developed 
Assay Reagents for Gene Expression (PE) were used, and reactions were performed 
according to the protocol included. The specificity of PCR primers was tested under 
normal PCR conditions in a thermocycler (Eppendorf Mastercycler Gradient). As an 
internal control, we used commercially available Tubulin primers, internal control 
primers and probe were added at 50nM concentrations. Step One Plus Real time 
PCR system Thermal cycling proceeded with 50 cycles at 95°C for 15Sec and 60°C 
for 1min. Data were analyzed using a Step One software V2.0 program from Applied 
Biosciences. Input RNA amounts were calculated with a multiple comparative method 
for the mRNAs of interest and Tubuline. Analyses were performed in triplicate for 
each data point. The results are expressed as ratio of given mRNA/Tubulin. 
 
3.5.2. Cloning of siglecd1-3 incorporated pDEF vector in CHO lec1 cell line 
In order to create stable cell lines for some CD33rSiglecs, the coding sequence for 
the first three C-terminus siglec domains (CD33, -5, -7, -8, and -10) including V-set 
domain was amplified from pCDM8 vector. This particular expression vector has no 
rhinovirus 3c protease proteolytic cleavage site and has no selection pressure marker 
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for creating stable cell lines. The coding sequence for siglec(s) d1-3 was cloned in 
the pDEF expression vector. The coding sequence contains internal restriction 
enzyme sites for SpeI/XbaI and BglII. So the amplified product from pCDM8 vector 
will also have these restriction endonuclease sites incorporated at the 5’ and 3’-ends, 
respectively. Thus, the amplified product can have the same cohesive ends as at the 
interfaces on the expression vector. pDEF vector has multiple cloning site including 
for XbaI and BamHI. The sense primer amplification product will have either SpeI or 
XbaI at the 5’-end and the antisense primer amplified product will have BglII interface 
at the 3’-end. So after restriction digestion, the amplification product cut with 
SpeI/XbaI and BglII and the expression vector cut with XbaI and BamHI will have the 
same cohesive ends.  
 
3.5.2.1. Amplification of DNA by PCR 
The source of the DNA used as template can be purified plasmid DNA or an entire 
colony of bacteria. If a colony is to be used as a template, a single colony was 
picked-up with a sterile toothpick from an agar plate in a PCR reaction tube, and then 
replica plate was prepared. All components were used as master mix and 50μL was 
added to each selected template DNA or bacteria colony. 
 
3.5.2.2. PCR with Taq polymerase 
A 0.2mL reaction tube (Biozym) was used for preparing the PCR mix with the Taq 
polymerase (MBI Fermentas). 
Component Stock Amount 
Template DNA or a bacterial colony picked  1ng  
Primer 1 (20 pmol/μL) 100 pmol 2μL 
Primer 2 (for the opposite strand) (20 pmol/μL) 100 pmol 2μL 
2mM dNTP mix (0.5mM dATP, dCTP, dGTP and dTTP) 2.5mM 5μL 
25mM MgCl2 0.2mM 5μL 
Taq reaction buffer 10-fol 1-fold 5μL 
Taq polymerase (1 unit/μL) 1 Unit 1μL 
ddH2O  ad 50μL 
 
The PCR was carried out under the following conditions in a thermal cycler from 
Eppendorf. 
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Process Temperature Duration Cycle 
initial denaturation: inactivation of nucleases and 
complete denaturation 
95°C 30 sec  
denaturation of the DNA 95°C 30 sec 
annealing (Tm) 56-65°C 30 sec 
polymerase reaction (continuous renewal/extension) 72°C 240 sec 
30  
final extension 72°C 1300 sec  
Cooling/hold 4°C   
 
3.5.2.3. PCR with pfu polymerase 
The Pfu polymerase was used provides an additional 3'-5’ exonuclease activity which 
is effectively a correction activity (Proof Reading).  
Component Stock Amount 
Template DNA   1ng  
Primer 1 (20 pmol/μL) 100 pmol 2μL 
Primer 2 (for the opposite strand) (20 pmol/μL) 100 pmol 2μL 
0.2mM dNTP mix (0.5mM dATP, dCTP, dGTP and dTTP) 10mM 1μL 
25mM MgCl2 0.2mM 5μL 
Reaction buffer MgSO4-10-fold 1-fold 5μL 
Pfu polymerase (2.5 unit/μL) 1.25 Unit 0.5μL 
ddH2O  ad 50μL 
 
The PCR was carried out under the following conditions in a thermal cycler from 
Eppendorf. 
Process Temperature Duration Cycle 
initial denaturation: inactivation of nucleases and complete 
denaturation 
95°C 30 sec  
denaturation of the DNA 95°C 30 sec 
annealing (Tm) 56-65°C 30 sec 
polymerase reaction (continuous renewal/extension) 72°C 240 sec 
30  
final extension 72°C 1300 sec  
Cooling/hold 4°C   
 
To control the PCR reaction 5μL of the reaction mixture was analyzed on an agarose 
gel. PCR product was purified either using the QIAquick PCR Purification Kit from 
Qiagen or from the agarose gel using QIAquick Gel Extraction Kit from Qiagen. 
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3.5.2.4. Purification of PCR products 
The purification was performed with the QIAquick? PCR Purification Kit (Qiagen). 5-
fold guanidine hydrochloride-containing buffer (PB) was added to the PCR product 
and then the PCR mixture was pipetted on the spin columns provided with the kit and 
centrifugation for 13000rpm at RT in Eppendorf MiniSpin. The flow through was 
discarded and the bound DNA was washed with 750μL of the ethanol-containing 
buffer (PE) by centrifugation. Then, 50μL EB buffer (10mM Tris-HCl pH 8.5) was 
applied to the column and incubated for 1min. Then the DNA was eluted into a 1.5mL 
reaction tube by 1min centrifugation. For control 2μL of DNA solution were analyzed 
on an agarose gel. 
 
3.5.2.5. Separation and extraction of DNA 
3.5.2.5.1. Agarose gel electrophoresis of DNA 
In an agarose gel electrophoresis, DNA fragments are separated according to size. 
The ethidium bromide intercalates with DNA and fluoresces under UV light, so that 
the DNA bands are visible after electrophoresis with UV light. Depending on the 
future use, a preparative comb (120μL volume) or an analytical comb (12μL volume) 
was used. Thereafter, 100μL or 10μL of sample was pipetted together with 15μL or 
1.5μL loading buffer and separated; the molecular weight standard was also added 
on the same gel. The electrophoresis was carried out for 30-60min at 100 volts. 
Then, the visualization of DNA bands was carried out on a UV-table at 405nm, using 
Herolab-Geldokumentations systems. 
 
3.5.2.5.2. DNA extraction from agarose gel 
On the UV table, the corresponding DNA bands were concisely cut from the agarose 
gel with a scalpel and transferred to 1.5mL reaction tubes. The weight of the gel 
piece (100μL?100mg) was determined (maximum 400mg) and the guanidine 
thiocyanate-containing buffer QG was added three times to the volume of gel piece. 
Then it was incubated for 10-minutes at 50°C mixed well for 2-3 times during 
incubation or until the gel had dissolved completely. The other steps were done 
similar to the QIAquick? PCR Purification Kit. 
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3.5.2.6. Plasmid 
The pDEF (Fc-3c) vector (pDEF) was provided by Dr. Crocker (Dundee, UK). The 
resistance gene for hygromycin B (HygR) under control of the SV40 late promoter 
allows a high copy number of the plasmid in transfected cells. This expression vector 
is for eukaryotic cells and has the eukaryotic transcription factor EF-1. With pDEF 
vector the transfected eukaryotic cells can be selected by resistance to hygromycin B 
and thus permanently stably transfected cells can be obtained. Furthermore, the 
vector contains also an origin of replication for bacteria (ori), for the reproduction of 
bacteria, and a gene for resistance to ampicillin, which allows the positive selection of 
transformed bacteria. The pDEF vector also includes the human IgG1 Fc portion, 
which includes the hinge region (hinge-CH2-CH2-CH3). This region has been 
modified and a proteolytic cleavage site is included for the rhinovirus 3c protease: 
pDEF (Fc-3c). 
In this vector, the coding sequences for the extracellular siglec domains were cloned, 
which are then referred to as siglec-Fc chimeras for expression. The expressed 
siglec-Fc chimeras can be separated by the protease interface after the successful 
expression of the Fc-part and three monomeric siglec-(Nr.)d1-3 parts. The vector 
contains interfaces for XbaI and BamHI in its multiple cloning site. The coding 
sequence of siglec-(Nr.)d1-3 (Rutherford et al., 1993; Gessani et al., 1993) was 
amplified from the expression vector pCDM8, together with the genomic sequence of 
the Fc portion of human IgG1. 
XnmI
BglII
Ef1a promptor
XhoI
XbaI
SpeI
BamHI
SmaI
PstI
PvuII
EcoRI
EcoRII
Sv40 polyA
HindIII
HSVTK polyA
ScaIHygR
HSVTK promotor
ColE1 Ori
ScaI
AmpR
pDEF
6.5 kbp
 
Figure 3.1: pDEF vector 
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3.5.2.7. Enzymatic modification of DNA 
3.5.2.7.1. Restriction digestion of DNA 
Using appropriate restriction endonucleases plasmid DNA is cut into defined 
fragments. These restriction endonucleases require certain buffers of the respective 
companies offered in 10-fold concentrated. In a digestion mix with two restriction 
endonucleases, the buffer suitable for both enzymes should be determined and used. 
The so-called MED-restriction buffer (10x buffer: 2.92% (w/v) NaCl/1.21% (w/v) Tris-
HCl pH 7.5/2.03% (w/v) MgCl2 +1mg/mL (w/v) BSA) can be used with most DNA-
modifying enzymes. 
Each reaction mix (10-50μL) contains the following components: 
1?g DNA 
20-10 units of each enzyme 
1/10μL of the specified volume of the corresponding 10-fold buffer 
ad 10-50μL ddH2O. 
The reaction mix is incubated for 2h at 37°C. The inactivation of the restriction 
endonucleases was achieved by heating the reaction mix to 70°C for 10min. The 
digested plasmids can be stored at -20°C until use. 
 
3.5.2.7.2. Ligation of DNA fragments 
Each ligation mixture (50μL) contains the following components: 
20ng vector DNA 
3-5 fold molar excess DNA (restriction digested) 
2 units T4 DNA ligase 
1/5μL of the specified volume of 5?buffer 
ad 50μL ddH2O 
The digested mix was incubated for 16h at 18°C. After incubation the ligation mixture 
was transformed into chemically competent E. coli. 
 
3.5.3. Plasmid DNA isolation and purification  
3.5.3.1. Plasmid ‘mini’ preparation of DNA 
QIAprep?miniprep Kit (Qiagen) was used for the preparation of small quantities of 
plasmid DNA. For this, the corresponding clone was grown in 2mL LB/Amp medium 
overnight at 37°C in shaker at 240rpm. 1.5mL of the overnight culture was 
centrifuged for 1min in an EppendorfminSpin. The bacteria pallet was resuspended in 
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250μL of P1-buffer (50mM Tris-HCl pH 8.0/10mM EDTA) with 250μL P2-lysis buffer 
(200mM NaOH/1% SDS), mixed by repeated inversion, and incubated for maximum 
5min at RT. The cell lysate was neutralized with 350μL P3-buffer (3M potassium 
acetate neutralized pH 5.5). After 10min centrifugation at RT (13,000rpm, 
EppendorfminiSpin), the supernatant was subjected to the provided silica columns for 
1min at RT and centrifuged (13,000rpm, EppendorfminiSpin). The eluate was 
discarded and the bound plasmid DNA was washed with 750μL of the ethanol-
containing PE-Buffer. Then the DNA was eluted with 50μL ddH2O. For control 2μL of 
DNA solution was analyzed on an agarose gel. 
 
3.5.3.2. Plasmid midi-preparation for DNA extraction 
For preparation of larger plasmid quantities HiSpeed? midiprep Kit (Qiagen) was 
used, a 200mL of overnight transformed E. coli culture was prepared. According to 
the manufacturer protocol plasmid DNA was purified after alkaline lysis of overnight 
bacterial culture using the supplied ion-exchange columns.  
The buffers P1-P3 correspond to those of the QIAprep? midiprep Kit. The overnight 
culture was transferred to a 50mL plastic tube and centrifuged for 10min at 4°C and 
4000rpm (Eppendorf table centrifuge 5810R). After decanting the supernatant the 
pellet was resuspended in a total of 6mL of P1 buffer, and then 6mL of lysis buffer P2 
was added to the mixture, mixed by inverting several times and incubated for 5min at 
RT. The cell lysate was neutralized by adding 6mL of P3 with repeated inverting. The 
lysate was added to an enclosed filter cartridge in which the cell material could be 
retained during 10min incubation. 4mL QBT buffer (750mM NaCl/50mM MOPS pH 
7.0/15% (v/v) isopropanol/0.15% (v/v) Triton X-100) was added to equilibrate silica 
gel column and then the lysate was filtered. The column was then washed with 20mL 
washing buffer QC (1M NaCl/50mM MOPS pH 7.0/15% (v/v) isopropanol) and the 
DNA was eluted from the column with 5mL elution buffer QF (1.15M NaCl/50mM 
Tris-HCl pH 8.5/15% (v/v) isopropanol). Then the DNA was precipitated with 3.5mL 
isopropanol by incubating for 5min with at RT and pressed through the 
QIAprecipitator? filter. The DNA was eluted with 1mL TE buffer (10mM Tris-HCl pH 
8.0/1mM EDTA) from the filter. 
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3.5.3.3. Determination of the plasmid DNA concentration 
The concentration and purity of a DNA-containing sample can be determined 
photometrically. The average absorption maximum of nucleic acids is at a 
wavelength of 260nm and the average maximum absorption of proteins at a 
wavelength of 280nm. From the ratio of E260/E280, which should be above 1.7, the 
purity of the DNA was determined. The absorbance at 260nm gives information about 
the concentration of DNA in a sample. Absorbance of 1 corresponds to approximate 
1mg/mL of double-stranded DNA. For the measurement of 1μL sample was diluted 
1:100 with TE buffer. DNA solution was measured at 260nm and 280nm. 
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4. Results 
4.1. Characterization of CHOLec1 produced siglec Fc-chimeras 
The glycocalyx covering the nucleated cells through its Sia derivatives along with 
siglecs is involved in various biological processes (Varki and Lowe, 2009).The 
possible immunomodulator roles of CD33rsiglecs have been discussed in the 
introductory chapter. These immunomodulator functions of CD33rsiglecs could be 
investigated through various Sia specific binding and inhibitory assays. As Sia 
expressed on the same cell/protein surface may influence these studies. Desialylated 
siglecs were derived from CHO cell line. This section will discuss siglec synthesis 
and quality control measures performed to get functionally active desialylated siglecs. 
 
4.1.1. Siglec Fc-chimera producing CHOLec1 cell lines 
CHOLec1 cell line is stably transfected with pDEF plasmids containing the first three 
domains of siglec-5, -7, -8, and -10, respectively, which are linked to the Fc part of 
human IgG (3.1.8.2.). Initially stably transfected cells were maintained in FCS 
containing ?MEM cell culture media (3.1.8.3). Stably transfected CHOLec1 cells 
secrete siglec Fc-chimera in cell culture media. Siglecs were purified using Protein A 
beads (3.3.2), as Protein A has specificity towards the Fc part. IgG depletion of FCS 
was necessary to avoid FCS-derived IgG contaminations in the produced proteins. 
However, this is a time consuming and expensive procedure (3.1.8.1.1). Moreover, 
total elimination of IgGs is not possible. To overcome these problems stably 
transfected CHOLec1 cell lines were adapted to chemically define synthetic EXCell® 
media (3.1.8.5). 
The optimal CHOLec1cell density for maximum siglec Fc-chimeras production was 
found to be 2-3?104/mL. This optimal cell density varies with the siglec Fc-chimera 
such cells are producing. The most effective production with highest cell density was 
obtained for siglec-7, where ~4mg/L of siglec-7 Fc chimeras was purified from 1L 
harvested cell culture supernatant. Every batch of supernatant harvested was tested 
using ELISA to check for secretion of siglec Fc-chimera and levels of production 
(3.2.2.2).  
 
4.1.2. Quality control for purified siglec protein 
Purified siglec Fc chimeras were run under reducing conditions in 10% SDS-PAGE 
(3.3.4.1). Proteins were visualised by silver staining for any contaminates (3.3.4.3), or 
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they were detected with anti siglec antibody in western blot (3.3.4.4.1). Under 
reducing conditions all the purified siglec Fc-chimeras ran at about 70 kDa (Figure 
4.1). Comparing the running behaviour of CHOLec1 cell line synthesised proteins 
verses CHOK1 cell line synthesised proteins, CHOK1 synthesised glycosylated 
siglec Fc-chimera ran slower. Whereas CHOLec1 produced desialylated (lacking 
complex N-glycane structures) siglecs run faster. Also the CHOK1 produced siglec 
Fc-chimera showed several unspecific protein bands.  
The nature of these extra bands was deduced with anti hu IgG antibody. Using this 
antibody, only a single band around 70 kDa was detected (Figure 4.1). Also the anti-
hu IgG directed against the Fc part does not bind to any of these (contaminating 
extra bands) proteins (data not shown).  
 
 
Figure 4.1: Silver staining and western blot detection of CHOLec1/K1 purified siglec Fc-
chimeras 
SDS-PAGE under reducing conditions: 2μg of CHOLec1/K1 produced siglec Fc-chimera loaded 
in each lane. Siglec Fc chimera bands visualized by silver staining. Siglec Fc-chimera band 
runs at around 72 kDa. CHOLec1 produced siglecs run faster as compared to CHOK1 produced 
siglecs. Anti siglec polyclonal antibody detects siglecs with high specificity in western blot 
analysis only. Anti siglec antibody detects CHOK1 produced siglecs more efficiently. 
 
4.1.2.1. Solid phase cell adhesion assay as a functionality test 
Siglecs can bind to naturally occurring Sia derivatives through their V-set domain. 
Erythrocytes surface is very rich with Sia derivatives; Sia dependent binding will give 
proof of the functionally active siglecs (3.2.2.3). The highest immobilized siglec 
concentration which is able to exert very compact erythrocyte binding (honey comb 
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structure) is described as being above the threshold concentration (Figure 4.2) of 
functionally active siglecs. In the subsequent dilution step this compact binding is lost 
and erythrocytes start regaining their original shape this concentration is referred to 
as being below the threshold concentration (Figure 4.2). This transformation is 
sudden and after this, the number of erythrocytes bound per well reduces rapidly with 
successive dilution steps (Figure 4.2). The erythrocytes free of Sia (3.4.1) were 
unable to exert any binding with the CHOLec1/K1 produced siglecs (Figure 4.2). 
 
Table 4.1: Threshold concentration (μg/mL) levels for CHOLec1/K1 produced and purified 
siglec Fc-chimeras in erythrocyte solid phase cell adhesion assay. 
Cell lines 
Siglec 
CHOK1 CHOLec1 
siglec-5d1-3Fc 0.2 0.2 
siglec-7d1-3Fc 0.1 0.05 
siglec-8d1-3Fc 0.8 0.8 
siglec-9d1-3Fc 0.2 0.1 
siglec-10d1-3Fc 0.4 0.4 
 
 
Figure 4. 2: Solid phase cell adhesion assay performed with CHOLec1 produced and purified 
siglec-5 Fc chimera 
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Starting with 0.8μg/mL a serial dilution of CHOLec1 produced, siglec-5 Fc-chimeras were 
immobilized on high binding plastic plate. In solid phase cell adhesion assay up to 0.2μg/mL of 
siglec-5 could exert above-threshold Sia mediated binding towards untreated erythrocytes. 
VCS-treated erythrocytes fail to show any binding with above threshold level immobilized 
siglec Fc-chimeras. Unspecific binding of erythrocytes to plastic plate surface was not 
observed. 
 
Among the CHOLec1/K1 produced siglecs, siglec-7 (0.05μg/mL) exerts the strongest 
binding towards untreated erythrocytes, whereas siglec-8 showed the weakest 
binding (Table 4.1). Upon comparing CHOK1 and CHOLec1 produced siglecs, 
CHOLec1 produced siglec-7 and -9 showed more efficient binding towards 
erythrocytes. As siglecs exhibit low affinity towards naturally occurring Sia derivatives 
(Blixt et al., 2003b), the uncomplexed siglec binding towards erythrocyte confirms 
that the siglecs produced in CHOK1 and Lec1 cell lines are functionally active and 
can be used in future binding and/or inhibition experiments. 
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4.2. Heterogeneity in siglec expression 
Siglecs are cell-surface proteins and are expressed on hematopoietic cell surface. 
Siglec shows a distinct hematopoietic cell specific expression pattern (von G.S. and 
Bochner, 2008). Some siglecs are broadly expressed while the expression of others 
is limited to few cell types (von G.S. and Bochner, 2008). Detailed analysis of siglecs 
expression on the cells of hematopoietic system is important to understand their 
exact role in immune responses. As myeloid progenitors, monocytes and 
macrophages are the cells to come first in contact with pathogens evading immune 
system. This chapter will elucidate the variations in siglec expression on 
mononuclear cells under different circumstances. Siglec expression analysis 
performed with flow cytometry. 
 
4.2.1. Efficiency of Ficoll/Percoll combined gradient 
Mononuclear phagocytes were obtained with buffy-coats obtained from human 
volunteers with Ficoll/Percoll combined density gradient (3.1.1). Table 4.2, shows the 
average monocyte-to-lymphocyte ratios over Ficoll/Percoll combined density 
gradient, with the average monocyte yield and recovery. The values showed here 
were obtained from 56 independent isolations experiments performed over a period 
of three years. The cell suspension composition was evaluated by flow cytometry 
with forward scatter (FSC) vs. side scatter (SSC) (3.2.1). Figure 4.3, shows 
enrichment of monocytes population with successive gradient steps (denoted by 
enclosed circle). 
 
Figure 4. 3: Enrichment of monocyte from total BC with Ficoll-Percoll gradient 
Typical leucocyte distribution on a FSC vs. SSC density plots. Monocytes have higher FSC 
values than lymphocytes and comprise a larger interval of SSC values. The indicated 
percentages of cells (monocytes) are relative to the total number of cells analysed (indicated 
by a enclosed circle). (A) ~14% enriched monocyte after first Ficoll gradient; (B) most 
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lymphocyte free monocyte-enriched culture after the hyper-osmotic Percoll gradient; (C) ~83 % 
enriched platelets and dead cells free monocytes population after iso-osmotic Percoll gradient.  
 
The mean percentage of monocytes in the starting MNC suspensions was 11±6%. 
The suspensions were highly contaminated with platelets, regardless of the number 
of washing steps. The ratio of monocytes to lymphocytes increased significantly after 
separation on hyper-osmotic percoll, and was further increase after iso-osmotic 
percoll gradient. The average purity of monocytes in the final suspensions was 
77±10% (Figure 4.3). The contaminating MNC were mainly T lymphocytes and NK 
cells. The separation on the iso-osmotic Percoll was crucial for eliminating platelets 
and dead cells although it resulted in some loss of monocytes.  
 
Table 4.2: The average monocyte yield and recovery obtained with the isolation of monocytes 
on a Ficoll/Percoll density gradient (MNC: mononuclear cells, SD: standard deviation, n: 
number of samples) 
Starting MNC 
suspension 
Final monocyte- 
Enriched suspension 
MNC 
yield 
Monocyte 
 
Monocytes (% ) Monocytes (% ) MNC 
Yield 
(?106) 
Recovery 
(% MNC) 
Mean value 11 75 703 77 13.5 
SD (n = 56) 6 10 238 36 6 
 
The viability of monocytes in the final suspension was 96% (data not shown). The 
average final cell yield was 13.5% based on the starting MNC numbers, as assessed 
by cell counting (3.1.2). This was also the approximate value of the average 
percentage of monocytes in the starting MNC suspensions, as assessed by flow 
cytometry. The average monocyte ratios in the starting and in the final cell 
suspensions were determined after calculating the average monocyte yield and 
recovery (Figure 4.3). Based of these values, the final monocyte recovery is ~75%. 
Moncyte percentage was derived with respect to total cells only after anti CD14 
antibody binding. 
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Figure 4.4: Gating monocytes in monocyte enriched PBMC sample 
A: 2-D density plot showing leukocyte distribution, monocytes having higher FSC values than 
lymphocytes and comprising a larger interval of SSC values (gate A) whereas lymphocytes 
having lower FSC value (gate B); B: 3-D density plot showing cells stained with anti-CD14 
antibody; (C) CD14 positive monocytes distribution on 3-D density plot (gate A). 
 
The isolated cells (monocytes) were stained with anti-CD14 antibody (monocyte 
specific surface antigens) and analysed by flow cytometry (3.2.1.3). As monocytes 
isolated with Ficoll/Percoll gradient were not very pure for siglec expression analysis 
it was necessary to locate them from total analysed cells. A homogeneous monocyte 
population (gate A) can be observed after anti-CD14 antibody binding (Figure 4.4). 
The efficiency of monocyte isolation is largely dependent on preparation of the 
Percoll gradients and errors in sample handling. 
 
4.2.2. siglec expression on mononuclear phagocytes  
Expression of siglec-1, -3, -5, -7, -9, and -10 was analysed on isolated mononuclear 
phagocytes. Siglec expressing monocytes was identified after double staining the 
cells with anti-CD14 (monocyte specific) and anti-siglec antibody (3.2.1.4)(Figure 
4.5). Peripheral blood-derived monocytes express up to five (siglec-3, -5, -7, -9, and -
10) of the known CD33rSiglecs on their surfaces. Figure 4.5 shows distribution of 
total PBMCs in a 3D density plot. All the cells do not express siglecs with the same 
efficiency. Monocytes expressing siglecs were typed only after found to be double 
positive (siglec and CD14)(Figure 4.5A and B). Sigelc-8 which is not expressed on 
monocytes was used as internal negative control (Figure 4.5C). The anti-CD14 
(monocyte) and anti-siglec antibody (siglec) positive double positive cells will cover 
larger distances in both the FL1 (FITC) and FL2 (PE) channels (Figure 4.5A and B).  
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Figure 4.5: Siglec expression on monocyte  
Monocyte specific siglec expression was typed using mouse anti-human siglec monoclonal 
antibodies (primary) together with PE-labelled donkey anti-mouse IgG antibodies (secondary). 
monocytes detected with FITC-labelled CD14 antibody. Cells were analysed using flow 
cytometry; (A, B and C) show 3D density of monocytes for, siglecs-7, -9 and -8 respectively. 
Double positive monocytes are indicated by enclosed circle. 
 
4.2.3. Siglecs expressed on human monocytes 
Monocytes isolated with percoll gradient method express siglec-3, -7, -5, -9 and -10 
(small population) (3.2.1.4)(Figure 4.6). In native state, siglecs are usually involved in 
cis-interactions with Sia derivatives present on same cell surface. Siglec-3 being the 
shortest is always covered by glycocalyx and hence could not be detected until after 
sialidase treatment of these cells. Siglec-9 showed highest level of expression on 
monocyte surfaces while siglec-5 and -7 showed intermediate expression levels. 
Siglec-10 expression is limited to small monocyte populations (1–10%) with high 
expression levels. Siglec-1 and -8 which are not expressed on monocytes do not 
show signals above the noise level. Monocytes do not express every siglec with 
same intensity. 
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Figure 4.6: Siglecs expression on native verses AUS-treated monocytes 
Mean fluorescence intensity (MFI) for siglec expression was measured with flow cytometry on 
FL2 log scale. Cells were stained with FITC-monoclonal mouse anti human siglec antibody and 
detected with PE-labelled anti mouse IgG antibodies. All cells analysed were positive for CD14, 
anti siglec-8 antibodies were used as a isotype matched control for monoclonal antibody. MFI 
values in bar chart represent the expression of the siglecs on human peripheral blood-derived 
monocytes before and after sialidase treatment. 
 
4.2.4. Changes in siglec expression upon differentiation and activation of 
monocytes and monocyte derived macrophages 
4.2.4.1. siglec expression on monocytes and monocyte derived macrophages 
Monocytes isolated from peripheral blood express siglec-3, -5, -7, and -9. This 
expression however changed upon adherence of the cells to culture dishes and in 
vitro differentiation to macrophages (3.1.3). Upon differentiation to macrophages, the 
level of cell surface siglec-3, -5, and -9 was strongly reduced whereas siglec-7 was 
increased (Figure 4.7). Interestingly, cell surface siglec-5 expression was reduced 
just after 15min of adherence, whereas changes of the other siglecs were observed 
only after several hours (data not shown). 
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Figure 4.7: Siglecs expression on human monocytes and monocyte-derived macrophages 
Peripheral blood-derived monocytes express siglec-3, -5, -7, -9, and -10. Cells were stained with 
FITC-monoclonal mouse anti siglec polyclonal antibodies followed by staining with PE-labelled 
anti mouse IgG Fab-fragments. Antibody binding was analyzed by flow cytometry. All cells 
shown were positive for CD14. Anti siglec-8 antibodies were used as isotype matched control. 
 
These recorded changes in siglec expression were highly reproducible and 
independent of the isolation method for the monocytes (isolation by negative 
selection using Miltenyi or Dynal negative selection kits (3.1.1.4), combined 
Ficoll/Percoll gradients (3.1.1.3) or adhesion to plastic surface (3.1.1.2)) and source, 
which could be either from BC or fresh peripheral blood in the presence of 
autologous serum or fetal calf serum (data not shown). 
 
4.2.4.2. Changes in siglec expression upon activation of mononuclear 
phagocytes with IFN? and IL-4  
Isolated monocytes were allowed to differentiate for 3-6 days to macrophages under 
M-CSF (3.1.3). The monocyte derived macrophages were activated in vitro by 
cytokines, IFN? and IL-4 (3.1.3.1). IL-4 (type-II) and IFN? (type-I) cytokine induced 
opposite changes in siglec expression (Figure 4.8). Activation with IL-4 leads to 
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upregulation of siglec-7, -9 and –10, while IFN? induces an upregulation of siglec-1 
and downregulation of siglec-7 and -9 (Table 4.3). All changes observed were 
reproducible in several independent experiments with cells from different healthy 
individuals. 
 
Figure 4.8: Siglecs expression on human monocytes and monocyte-derived macrophages 
Activation with IL-4 leads to an up regulation of siglec-7, -9 and –10, the IFN? induces an up 
regulation of siglec-3 and down regulation of siglec-7 and -9. Cells were stained with 
monoclonal mouse anti siglec polyclonal antibodies followed by staining with PE-labelled anti 
mouse IgG Fab-fragments. Antibody binding was analyzed by flow cytometry. Anti siglec-8 
antibodies were used as isotype matched control. 
 
Table 4.3: Changes in siglec expression upon activation with IFN? and IL-4 
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4.2.4.3. Availability of siglec Sia binding sites on unactivated and activated 
mononuclear phagocytes 
The availability of Sia binding sites for trans-interactions as well as their involvement 
in cis-interactions is important in determining siglecs functions. This raises the 
question whether siglec Sia binding sites on mononuclear phagocytes are available 
for trans-interactions. Therefore, the binding of polyvalent PAA-derivatives carrying 
sialylated oligosaccharides as probes to monocytes and macrophages was analysed, 
using the corresponding 6´-O-sulfo-lactose derivative as negative control (3.2.1.2). 
Binding of the sialylated probes carrying ?2,3-sialyllactose, ?2,6-sialyllactose, Sialyl-
Lewisx or Sialyl-Lewisa was observed in AUS desialylated cells (Figure 4.9). 
The Sia binding sites of siglec-3, -5, -7, and –9 present on monocular phagocyte cells 
are involved in cis-interactions. Robust binding was obtained with probes carrying 
?2,3-linked Sia (?2,3-sialyllactose, Sialyl-Lewisx, followed by Sialyl-Lewisa), whereas 
probes bearing ?2,6-sialyllactose were barely bound (Figure 4.9), reflecting the 
glycan specificities of siglecs present on these cells. Furthermore, differentiation to 
macrophages or activation of these cells with either IL-4 or IFN? for 5min, 15min, 1h, 
3h, 1d, 2d, 3d did not result in unmasking of siglec Sia binding sites (data not 
shown). 
 
Figure 4.9: The availability of siglec Sia binding sites on human monocytes and monocyte-
de<rived macrophages. 
Cells were stained with biotinylated PAA-oligosaccharide probes followed by detection of 
bound probes with PE-labelled streptavidin. Probe binding was analyzed by flow cytometry. As 
a negative control, 6´-O-sulfo lactose probe was used. Also in order to see whether binding 
sites are occupied by cis-interactions, control cells were treated with sialidase prior to binding. 
With the native control no binding above noise level has been obtained with monocytes for any 
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of the tested probes viz. ?2,3-sialyllactose, ?2,6-sialyllactose, Sialyl Lewisx or Sialyl Lewisa. 
After sialidase treatment binding of ?2,3-sialyllactose and Sialyl Lewisx was higher than 
binding of ?2,6-sialyllactose or Sialyl Lewisa.  
 
4.2.5. Siglec expression on monocytes is donor dependent 
The studied population showed that monocyte siglecs do not have a same 
expression level. The studied healthy adult individuals exhibit differential levels of 
every siglec expression. It was observed that Siglec-9 is the most diversely 
expressed siglec on monocytes (Figure. 4.10). Siglec-10 also has a very wide range 
of expression but its expression is limited to a small monocyte population (1-10%). 
Siglec-3, -5, and -7 showed moderate variations in their expression levels whereas 
sigelc-1 and -8 were not detected on monocytes. 
 
Figure 4.10: siglec expression on monocytes is donor dependent 
Monocytes were isolated from buffy-coats and monocyte surface siglec expression profile was 
created for 52 individuals. Mean fluorescence intensity was determined with flow cytometer 
(FL1) and plotted on a dot plot. Each dot represents particular siglec expression for individual 
donor. 
 
4.2.6. Six month siglec expression profile on monocytes 
Regularity in siglec expression on monocytes from individual volunteers was 
determined; blood samples were collected from the same 15 donors for six months 
every 2 weeks. And six month monocyte siglec expression profile was created for 
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each individual. Siglec-7 and -9 expression levels were monitored for their 
consistency in expression on monocytes. Siglec-8 expression was also monitored as 
negative control (data not shown). 
Six month siglec profiling revealed that for a volunteer at any given time, siglec-9 
shows the most diverse expression. Siglec-7 showed moderate deviation from its 
basal expression levels. Volunteers also reported if they were ill at the time of blood 
collection. Donors who did not had any apparent signs of illness showed moderately 
consistent siglec expression levels (Figure 4.11A). Most of the cases where the 
volunteer reported ill, siglec-9 expressions showed larger deviation from its basal 
expression level (Figure 4.11B). 
 
Figure 4.11: Six months siglec expression profile for two individuals 
Samples were collected from 2 different donors every 15 days for six months. Siglec-7 and-9 
expressions profile for six month. (A) Donor not reported ill shows relatively consistent siglec 
expression profile. (B) Donor with illness indication at the time of sample collection. 
 
4.2.7. Co-relation between siglec and CRP-expression levels 
Under normal circumstances human CRP has low expression level (0.1–0.5 ?g/mL) 
but under inflammation condition the CRP levels are elevated approximately a 1000-
fold (Simmons and Seed, 1988). CRP levels in blood serum samples collected from 
the volunteers were measured with CRP-Assay (3.2.2.4). CRP levels were plotted 
against the siglec expression level for particular time point for each volunteer. In most 
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of the cases where the volunteer reported an apparent sign of illness, the high siglec-
9 levels coincided with higher serum CRP levels (Figure 4.12). In a case where the 
volunteer received vaccination against seasonal Influenza virus during the course of 
study, showed elevated siglec-9 expression levels coinciding with higher CRP levels. 
This elevation in either siglec-9/CRP level is comparable with siglec-9/CRP 
expression level when individuals reported ill.  
 
Figure 4.12: Siglec-9 expression on monocytes and its relation with serum CRP levels 
(A) Siglec-7 and-9 expressions profile for six month: red and blue dot represent that donor 
reported ill at the time of sample collection while green and pink dot represents collections 
made after vaccination. (B) Serum CRP levels profile (sample no 1, 2, and 13 are missing).  
 
4.2.8. Differences in siglec expression between different ethnic groups 
Among the studied volunteers, individuals belonging to the same ethnic group found 
to have more or less the same siglec expression levels. The most diversely 
expressed siglec, siglec-9, has a comparatively higher expression level in volunteers 
with Caucasian origin than in volunteers with Asian origin. Siglec-7 expression is 
more or less the same in both ethnic groups (Figure 4. 13).  
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Figure 4.13: Differences between Caucasians vs. Asian ethnic groups in monocyte surface 
siglec-7 and -9 expressions. 
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4.3. Influence of viruses on siglecs expression on monocyte surfaces 
Monocyte surface siglec expression is donor dependent and expression levels were 
found to vary over time and immune status of an individual. After correlating siglec 
expression levels with CRP levels, indicate that variations in siglec expression could 
be a result of changes in immune status. Some reports showed that pathogens use 
siglecs Sia recognising ability to invade immune system or vies a versa. This could 
either lead to elimination of the pathogen or disease progression. Role of siglec in 
early pathogen recognition stages was investigated after co-culturing monocytes in 
suspension cultures with different viruses. Changes in monocyte surface siglec 
expression were monitored and analysed with flow cytometry. 
 
4.3.1. Quantification of viruses 
Different viruses were cultivated and purified as described in the methods section 
(3.1.5). The hemagglutination activity of Influenza virus strain A/PR8/34 was tested 
for functionality. Serial dilutions of influenza were incubated with chicken 
erythrocytes. Up to a dilution of 1:640 virus was able to elicit rosettes formation. The 
HA titer value for influenza virus strain A/PR8/34 was determined to be 640.  
Functional activity for HAV-7 (immunocytochemical analysis) and Coxsackie viruses 
(cytopathic activity) was tested. HAV-7 infects and propagates in host cells without 
destroying them. TCID50 value for HAV-7 was therefore determined with the help of 
immunocytochemical analysis. FRHK4 cells were infected with serial dilutions of 
HAV-7 virus and incubated for two weeks before immunocytochemical analysis for 
virus detection. TCID50 for HAV-7 was determined to be 105mL. In the case of 
Coxsackie B virus cytopathatic activity exerted on FRhK4 cells was determined and 
was found to be 108mL. CMV and HAV-GBM virus preparations were available as non 
purified cleared cell lysates and purified NDV was available with a titer of 4?106.  
 
4.3.2. Siglec expression on monocyte surfaces is altered upon co-culture 
with viruses 
4.3.2.1. Co-culture of monocytes with enveloped viruses 
Monocytes in suspension culture were co-cultured with enveloped viruses (Influenza 
virus, NDV, and CMV) for 24h at 37°C (3.1.6.1). Presence of these viruses in co-
culture system influence siglec expression. Influenza virus which recognises Sia 
derivatives on host cell surface for infection and disease progression affected siglec 
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expression on monocytes the most. Significant decrease in siglec-5, -7, -9, and -10 
expression levels was recorded, and a significant increase in siglec-3 expression was 
observed (Figure 4.14). Siglec-3 detection was very unusual as under normal 
conditions sialidase treatment is required for siglec-3 detection. This is because 
Siglec-3 is usually covered by the cell’s glycocalyx.  
NDV which has a similar envelope structure as Influenza virus doses not affect siglec 
expression similarly. Co-culture with NDV leads to significant increase in monocytes 
siglec-7 and -9 surface expressions and shows a significant decrease in monocyte 
siglec-10 surface expression (Figure 4.14). Except siglec-9 whose expression 
decreased upon co-culture with CMV, all other siglecs expression remained 
unaffected with regard to this very virus. (Figure 4.14). 
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Figure 4.14: Changes in siglec expression upon infection with enveloped viruses  
Each enveloped virus affects siglec expression differentially; siglec-9 expression is affected by 
all three viruses. Siglec-1 and -8 were used as internal negative control as they are not 
expressed on monocytes. (A, B, and C) Influenza, NDV, and CMV virus were co-cultured 
individually with monocytes in suspension culture for 20h at 37°C under 5% CO2. Cells were 
then stained with monoclonal anti siglec antibody before analysing with flow cytometry. 
Changes in siglec expression [MFI] were calculated as % of initial siglec expression from 9 
independent experiments for statistical significance (n = 9). 
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4.3.2.2. Influence of non-enveloped viruses on monocytes siglec expression 
Two strains of HAV virus were used to co-culture with monocytes in suspension. 
Increase in siglec-7 and -9 on monocytes’ surface expression was detected (Figure 
4.15) in presence of both the HAV strains. Additionally HAV-GBM co-culture leads to 
a significant increase in siglec-5 expression level on monocytes (Figure 4.15). Co-
culturing Coxsackie B2 virus with monocytes resulted in a significant decrease of 
siglec-7, -9, and -10 expression levels. Siglec-1 and -8 which are not expressed on 
monocytes showed no changes in their expression and therefore were considered as 
internal negative controls. 
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Figure 4.15: Effect of non-enveloped virus co-culture on monocyte surface siglec expression 
Non-enveloped viruses affect monocyte surface siglec expression. (A, B, and C) Coxsackie B2 
virus, HAV-7, and HAV-GBM virus were co-cultured individually with monocytes in suspension 
culture for 20h at 37°C under 5% CO2. Cells were then stained with monoclonal anti siglec 
antibody before analysing with flow cytometry. Changes in siglec expression [MFI] were 
calculated as % increase or decrease of initial siglec expression from 9 independent 
experiments for statistical significance (n = 9).  
 
Sigelc-9 surface expression on monocytes was affected by all the viruses. There is 
no connecting link between type of viruses used for co-culture and changes observed 
on monocyte surface siglec expression, as each virus affects siglec expression 
differently. Changes in monocyte surface siglec expression are summarised in Table 
4.4. 
 
 
 
 
 
 
 
 
 
 
 
 Results 70 
 
Table 4.4: siglec expression changes on monocytes upon co-culture with viruses 
Siglecs 
Virus 
1 3 5 7 8 9 10 
Influenza N.C. 
 
N.C. 
 
NDV N.C. N.C. N.C. N.C. 
 
CMV N.C. N.C. N.C. N.C. N.C. 
 
N.C. 
Coxsackie 
B2 
N.C. N.C. N.C. N.C. 
 
HAV-7 N.C. N.C. N.C. N.C. 
 
N.C. 
HAV-GBM N.C. N.C. N.C. 
 
N.C. 
Keyset: N.C. = not changed; ? = increased expression; ? = decreased expression 
 
4.3.3. Effect of co-culture time on virus mediated monocyte surface siglec 
expression 
Influenza, HAV-7 and Coxsackie B2 seem to affect a wider range of siglecs on 
monocytes compared with the other viruses. These viruses were selected to 
investigate further for their influence on siglec expression. Monocytes in suspension 
culture were co-cultured with these viruses between 0-120 min. Such a short time 
exposure of monocytes to viruses leads to changes in the expression of siglecs on 
monocytes surfaces. Changes in siglec expression were detected as early as after 
10min of co-culture. Results are in accordance with previous experiment. A 
significant increase in siglec-3 and a decrease in siglec-5, -7, -9, and -10 expression 
was recorded. HAV-7 co-culture resulted in rapid increase in monocyte siglec-7 and -
9 expression level. Co-culturing monocytes with Coxsackie B2 virus showed very 
complex siglec expression changes. Monocytes initially showed a rapid increase in 
siglec-9 expression which was eventually lowered down over co-culture time, 
whereas initial low expression level of Siglec-7 showed a sharp increase after 40min 
which was then lowered to reach its native expression levels at the end of 120min co-
culture time. These changes in siglec expression had very large standard deviation, 
and do not have any statistical significance. Mock-treated and native monocytes do 
not show any significant deviation from their native siglec expression levels. 
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Figure 4.16: Time mediated siglec expression changes exerted on monocyte. 
Effect of co-culture time on virus mediated monocyte surface siglec expression. (A, B, and C) 
Influenza, HAV-7, and Coxsackie B virus were co-cultured individually with monocytes in 
suspension culture between 0-120min at 37°C under 5% CO2. Cells were then stained with 
monoclonal anti siglec antibody before analysing with flow cytometry. Changes in siglec 
expression [MFI] were calculated as % increase or decrease of initial siglec expression from 9 
independent experiments for statistical significance (n = 9). 
 
4.3.4. Effect of time vs. virus concentration on monocyte siglec-7 and -9 
expressions 
Presence viral particles in monocyte co-culture system leads to changes in monocyte 
surface siglec expression. The number of viral particle in co-culture with these cells 
could be critical as in most cases virus dose is the limiting factor for successful 
invasion and disease progression. Influenza virus and HAV-7 viruses were selected 
for these experiments. Three different viral dilutions (1:100, 1:1000, and 1:10000) 
along with undiluted sample were tested. Changes in siglec-7 and -9 expressions on 
monocytes surface were monitored.  
Lowering the virus concentration in co-culture system showed a direct influence on 
siglec expression. The monocyte siglec expression remains unaffected at lower virus 
concentration (Figure 4.17). As virus concentration increases in the co-culture 
system, the effect exerted (changes in siglec expression) becomes more prominent. 
Results are in accordance with time-dependent siglec expression changes 
experiments. As Influenza virus and monocytes co-culture time progresses, a steady 
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decrease in siglec-7 and siglec-9 expression on monocyte surface was observed 
(Figure 4. 17) and this effect was more prominent with undiluted virus sample verses 
1:10000 diluted samples where siglec expression changes are not very evident.  
 
 
Figure 4.17: Effect of Influenza virus dose and co-culture time on monocyte surface siglec-7 
and -9 expressions 
Influenza virus was co-cultured with monocytes in suspension culture between 0-120min at 
37°C under 5% CO2. Cells were then stained with monoclonal anti siglec antibody before 
analysing with flow cytometry. Changes in Siglec-7 (A) and -9 (B) expression [MFI] were 
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calculated as % increase or decrease of initial siglec expression from 9 independent 
experiments for statistical significance (n = 9). 
Co-culturing monocytes with HAV-7 virus also resulted in a steady time verses virus 
concentration-dependent increase in siglec-7 and siglec-9 expression on monocyte 
surface (Figure 4. 18). This suggests that there is direct relation between numbers of 
virus particle getting in contact with the monocytes over time. Changes observed in 
siglec-7 and -9 expressions were reproducible in several independent experiments 
with cells from different healthy donors. 
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Figure 4.18: Effect of HAV-7 virus dose and co-culture time on monocyte surface siglec-7 and -
9 expressions. 
HAV-7 virus was co-cultured with monocytes in suspension culture between 0-120min at 37°C 
under 5% CO2. Cells were then stained with monoclonal anti siglec antibody before analysing 
with flow cytometry. Changes in Siglec-7 (A) and -9 (B) expression [MFI] were calculated as % 
increase or decrease of initial siglec expression from 9 independent experiments for statistical 
significance (n = 9). 
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4.4. Siglec interaction with tumour cells 
The phenotypic change in malignancy often correlates with a dramatic transformation 
of cellular glycosylation due to changes in the activity of one or more 
glycosyltransferases, during the process of transformation from normal to tumour 
cells (Oberling, 1997a). This may in turn be able to influence the tumour cell 
recognition by siglecs presented on mononuclear phagocytes. It has been shown that 
the contact of tumour cells with siglecs leads to increased cytokine secretion, and 
could finally influence disease progression. It will be interesting to investigate the time 
kinetics of cytokine secretion in presence of K562 erythroleukemia tumour cells. 
Inhibition of these activation processes in presence of inhibitory monoclonal anti 
siglec antibody will also be investigated. 
 
4.4.1. Binding of siglec-Fc chimera to K562 tumour cells 
Along with cytokines, cell-cell contacts can activate monocytes or macrophages. 
Sialylated carbohydrate structures on tumour cell membranes, i.e. on K562 
erythroleukemia cells induce activation of monocytes (Valdez and Perdigon, 1991a). 
Siglecs could be involved in this activation, since no other Sia specific lectins are 
present on mononuclear phagocytes. This hypothesis predicts the presence of siglec 
binding partners on the corresponding tumour cells. To check this hypothesis that 
binding partners for siglecs exists on tumour cells, the Sia dependent binding of 
CHOLec1 produced Fc-chimera to K562 tumour cells was analysed (3.2.1.1). The 
highest binding was observed for siglec-7 Fc, followed by siglec-10 Fc, and siglec–1 
Fc, whereas siglec-5, -8, and -9 Fc chimera did not show any detectable binding. In 
most cases siglec-9 Fc binding was very low, in some experiments a small population 
(1-10 %) of K562 tumour cells bound siglec-9 Fc at levels between siglec-7 Fc and 
siglec-10 Fc (data not shown). For all siglecs the binding observed was Sia-
dependent as confirmed by cells treated with AUS leading to reduced signal levels.  
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Figure 4.19: Binding of non-complexed CHOLec1 produced siglec Fc-chimeras to K562 tumour 
cells. 
Siglec Fc-chimeras were allowed to bind to K562 tumour cells and were detected with PE-
labelled anti human IgG-Fc antibodies. Sia-independent binding is shown by desialylation of 
K562 tumour cells by AUS. Binding was analyzed by flow cytometry. Siglec-1, -7, and 10 Fc 
shows binding to K562 tumour cells, whereas siglec-5 -8, and-9 Fc bind with less efficiency or 
show no binding to K562 tumour cells.  
 
4.4.2. Accumulation of siglec-7 at contact sites between two cell types 
Since siglec-7 binding to K562 tumour cells was higher than the other siglecs tested, 
this study is focused on siglec-7 involvement in direct cell-cell interaction between 
mononuclear phagocytes and K562 tumour cells. If siglec-7 plays a role in 
mononuclear phagocyte activation by tumour cells, accumulation of this siglec at 
contact sites between these cells can be expected. This question was addressed by 
performing an immunocytochemical analysis of K562-monocyte co-cultures (3.2.4). It 
was observed that siglec-7 accumulated at the contact site between the two cell 
types, whereas siglec-7 was evenly distributed over monocytes which are not in 
contact with K562 tumour cells (Fig. 4.20). This suggests that the interaction of 
 Results 78 
siglec-7 with glycoconjugates present on K562 cell surfaces is strong enough to cap 
the binding partners at the contact sites. 
 
Figure 4.20: Accumulation of siglec-7 at the cellular synapse between monocytes and K562 
tumour cells. 
Monocytes (M) in co-culture with K562 tumour cells (T) were co-cultured in RPMI / 2.5% 
autologous serum for 8h at 37°C under 5% CO2. Cells were fixed before staining anti Siglec-7 
monoclonal antibody; shown here is siglec-7 accumulation at the contact site between the two 
cell types (arrowheads). 
 
4.4.3. Cell surface sialoglycoconjugates of K562 tumour cells induce IL-6 
production in monocyte derived macrophages  
The potential of tumour cells to induce cytokine secretion by marophages was 
reinvestigated before addressing the question about the role of siglecs in this 
process.  
 
4.4.3.1. Cytokine secretion by mononuclear phagocytes in presence of K562 
tumour cell 
Monocyte-derived macrophages and K562 tumour cells were selected as model 
cells, since K562 tumour cells are highly sialylated and bind several siglecs found on 
macrophages as shown above (4.4.1). Induction of IL-6 secretion required the 
presence of K562 tumour cells (3.1.6.1). If the tumour cells have been desialylated 
before the co-culture with macrophages (3.4.2), heterogeneous results were 
observed. Upon co-culture with IFN? pre-treated macrophages and desialylated K562 
tumour cells had no effect on its activation, but markedly reduced levels of IL-6 
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secretion by unactivated macrophages in the presence of desialylated K562 tumour 
cells were observed in some experiments. However, the level of reduced IL-6 
secretion varied between 10 and 60% of that obtained with untreated K546 tumour 
cells (data not shown)(3.2.2.1). IL-4 pre-activated macrophages failed to respond to 
K562 tumour cell preparations. These observations suggest that K562 tumour cells 
may be able to induce IL-6 secretion by macrophages through sialylated cell surface 
glycoconjugates, but this effect may depend on the activation status of the 
macrophages. 
 
Figure 4.21: IL-6 release by pre-activated macrophages upon co-culture with sialidase-treated/ 
untreated K562 tumour cells 
Macrophages were co-cultured with untreated K562 tumour cells in RPMI / 2.5% autologous 
serum overnight at 37°C under 5% CO2; macrophages were either pre-activated with IFN? or IL-
4 or were non-activated. Non-activated macrophages produced ~110pg/mL of IL-6 upon co-
culture with K562 tumour cells, whereas sialidase-treated K562 tumour cells failed to activate 
macrophages. Macrophages pre-activated with IFN? produced similar amount of IL-6 in the 
presence of K562 tumour cells, however failed to show Sia dependent activation. Cells pre-
activated with IL-4 were not activated upon co-culture with K562 tumour cells. 
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4.4.3.2. Time kinetics of IL-6 release by macrophages in the presence of K562 
tumour cells 
The activation process induced by the tumour cells was closely monitored for the 
time course of IL-6 release by macrophages in the presence of untreated or 
sialidase-treated K562 tumour cells. Surprisingly, ~10pg/mL of IL-6 was detected 
after 30min in co-cultures with untreated K562 tumour cells, whereas in the co-culture 
supernatants with AUS-treated tumour cells, no detectable amounts of IL-6 were 
released within the first 6 hours. In control experiments using LPS to activate the 
macrophages, detectable IL-6 levels (>2pg/mL) were found only after 1 hour of 
incubation (3.2.2.1). 
 
Figure 4.22: Time-dependent IL-6 production of macrophages after co-culture with K562 
tumour cells.  
Monocyte-derived macrophages were co-cultured with sialidase treated/untreated K562 tumour 
cells, IL-6 elicit was estimated. Untreated K562 tumour cells activated macrophages rapidly and 
even after 30min of co-culture ~10pg/mL of IL-6 can be measured in cell culture supernatant. 
Sialidase treated K562 tumour cells took much longer. The positive control for macrophage 
activation by LPS took a longer time. 
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4.4.3.3. K562 tumour cells surface sialoglycoconjugate induced IL-6 
production 
To investigate whether the quick release of IL-6 is caused by the sialylated 
glycoconjugates present on tumour cell surfaces, crude membrane preparations of 
K562 tumour cells were used to activate the macrophages. The results obtained were 
consistent with the results obtained from intact K562 tumour cells co-culture 
experiments (3.1.9). After 30 min, ~4pg/mL of IL-6 was detected in co-culture 
supernatants of macrophages incubated with K562 cell membranes (Figure 4.23). 
Macrophages were not activated if membranes had been sialidase treated prior to 
co-culture with macrophages (data not shown). The overall response was weaker 
than that elicited by intact K562 tumour cells, since membrane preparations were 
expected to take longer time to get in contact with macrophages as compared to 
intact K562 tumour cells. The induction of cytokine secretion elicited by the 
membrane preparations was faster and stronger than with LPS during the first two 
hours. 
 
Figure 4.23: Time dependent IL-6 secretion by macrophages in presence of K562 tumour cell 
membrane preparations.  
Only the K562 membrane preparations were able to activat macrophages. Upon co-culture with 
undiluted K562 tumour cell-membrane preparations, macrophage became activated and even 
after 30min of incubation ~4pg/mL of IL-6 was measured in the culture supernatant. Positive 
controls for macrophage activation, using LPS, also took a longer time. 
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4.4.3.4. K562 tumour cells vs. K562 tumour cell surface sialoglycoconjugate 
induced IL-6 production 
Overall K562 tumour cell surface sialoglycoconjugate-induced IL-6 production was 
weaker than that elicited by intact K562 tumour cells. It could well be dependent on 
the time taken by membrane preparations to get in contact with macrophages. 
Results from parallel experiments were consistent with previous data. Untreated 
K562 tumour cells/membrane preparations were able to induce IL-6 production very 
early upon co-culture with either K562 tumour cells or K562 tumour cell membrane 
preparations; whereas LPS mediated IL-6 release response took a longer time. 
 
Figure 4.24: Time dependent IL-6 secretion by macrophages in presence of K562 tumour cell 
and membrane preparations 
Macrophages were co-cultured with untreated and sialidase treated K562 tumour 
cell/membrane preparations and early Sia dependent activation was recorded. Presence of 
untreated K562 tumour cells macrophages released ~10pg/mL of IL-6 in co-culture after the 
first 30 min, whereas untreated K562 tumour cell-membrane preparations took 120min to 
release approximately the same amount of IL-6. A partial Sia dependency was obtained in time 
with AUS-treated K562 tumour cells and membrane preparations. LPS was used as positive 
control for macrophage activation. 
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4.4.4. Sialylated K562 tumour cells induce early IL-6 mRNA synthesis  
To investigate if sialylated k562 tumour cells induce early IL-6 mRNA, real time PCR 
was carried out with the macrophage samples after co-cultured with K562 tumour 
cells (3.5.1). The K562 tumour cell surface sialoglycoconjugate induces early IL-6 
mRNA synthesis. Figure 4.25 demonstrates that 30min of co-culture of macrophages 
with K562 tumour cells lead to synthesis of IL-6 mRNA. IL-6 mRNA synthesis was 
measured against the house keeping tubulin gene. An initial 400-fold increase of IL-6 
mRNA levels was enhanced 4000-fold after 120 min. The LPS induced macrophages 
took longer to synthesise any detectable IL-6 mRNA. Similar results were obtained 
for IL-1? mRNA (data not shown). K562 membrane preparations took a longer time to 
elicit the IL-6 mRNA synthesis as they took longer to get in contact with macrophages 
(data not shown). 
 
Figure 4.25: IL-6 real time PCR: relative quantity plot compared to the baseline sample for IL-6 
mRNA from monocyte-K562 tumour cell co-culture system.  
RNA samples from untreated K562 tumour cells and macrophages co-culture system were 
used to determine IL-6 mRNA levels. 30 co-culture sample showed increased level of IL-6 
mRNA, whereas LPS activated sample took longer.  
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4.4.5. Secretion of IL-6 and IL-1? by mononuclear phagocytes is induced by 
K562 tumour cells possibly through interaction with siglec-7 
As demonstrated above, cell surface glycoconjugates of K562 tumour cells can 
induce Sia dependent activation of mononuclear phagocytes suggesting that siglecs 
are involved in these processes. Furthermore, siglec-7 appeared to be the most likely 
candidate, since (1) it showed the highest binding to K562 tumour cells, (2) it 
accumulated at the contact sites between two cell types, and (3) it affinity-precipitated 
more potential binding partners from K562 tumour cells surface than other siglecs 
(master thesis by Sarang Limaye). To address this hypothesis, the cytokine secretion 
by mononuclear phagocyte was blocked using anti siglec-7 mAb before co-culture 
with K562 tumour cells. This antibody does not activate the macrophages Siglec-7 on 
mononuclear phagocyte surface was blocked using monoclonal anti siglec-7 mAb 
before co-culture with K562 tumour cells. The efficiency of Sia dependent cytokine 
elicitation by macrophages was monitored. In the presence of anti siglec-7 mAb, 
~30% inhibition in IL-6 elicitation was recorded (Figure 4.21). The AUS treated K562 
tumour cells were unable to activate macrophages.  
Indeed, macrophages produced up to 40% less K562-induced cytokines in the 
presence of anti siglec-7 mAb. This indicates that the K562-mediated activation of the 
macrophages may be mediated at least to some extent through interaction of siglec-7 
with sialylated glycoconjugates on the K562 tumour cells. 
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Figure 4.26: IL-6 production by macrophages upon co-culture with K562 tumour cells in the 
presence of blocking monoclonal sheep anti siglec-7 antibody.  
K562 tumour cell-exerted Sia-dependent activation of macrophages is mediated by siglec-7. 
Siglec-7 is blocked by anti-siglec-7-mAb and the IL-6 secretion was monitored. After 30min co-
culturing macrophages and untreated K562 tumour cells in the presence of anti-siglec-7-mAb a 
~30% decrease in activation can was detected. AUS-treated K562 tumour cells failed to activate 
macrophages. Just the anti-siglec-7-mAb was not able to elicit activation of macrophages.
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5. Discussion 
Siglecs show a very high hematopoietic cell type restricted expression pattern (Table 
1.1), in particular the CD33rsiglecs have more complex expression patterns on 
mononuclear phagocytes (O'Reilly and Paulson, 2009). Siglecs also have the ability 
to recognise distinct and varied sialoside sequences on glycoprotein and glycolipid 
glycans which  are expressed on the same cell (in cis-) or on pathogen (bacteria, 
viruses), or tumour cells (in trans-) (Crocker and Redelinghuys, 2008). They also take 
part in immune processes through cytoplasmic ITIM and ITAM. To investigate further 
their role in immune system modulator processes. Complex siglec expression 
patterns on mononuclear phagocytes were analysed. Nearly untouched monocytes 
were used for this analysis. Monocytes and monocyte-derived macrophages were 
obtained by Ficoll/Percoll density gradient method and results were compared with 
other monocyte isolation protocols like adhesion to plastic surface and negative 
selection method. Variable cell counts were obtained with the adherence to plastic 
surface method and monocyte count was inversely proportional to the purity of the 
monocytes. Major drawback of the adherence to plastic surface method is they need 
to be detached before flow cytometry analysis. The negative immuno-selection 
monocyte isolation method is advantageous for the therapeutic applications but very 
expensive for research work. The monocytes isolated with Ficoll/Percoll isolation 
procedure have a similar purity to that obtained by the negative immuno-selection 
monocyte isolation method. The only disadvantage of Ficoll/Percoll procedure is 
platelets contamination, which could not be removed efficiently by low-speed 
centrifugation. The Ficoll/Percoll method is a simple, reliable, and cost-effective for 
isolating monocytes either from buffy-coats or whole blood samples. The yield of 
~75% and the purity of ~75% are comparable to the other isolation methods.  
Peripheral blood derived monocytes express siglec-3, -5, -7, -9, and -10 (1-10%). 
Upon differentiation to macrophages a general trend of decrease in siglec-3, -5 and -
9 and increase for siglec-7 expression was observed in all experiments, the level of 
expression and degree of change during differentiation varied between individual 
donors. A comparison of siglec expression on monocytes isolated from the same 
donor at different time intervals over several months provided evidence that siglecs 
expression levels are variable, and these changes are probably refection of the 
immune status at that instance. A comparison of siglec expression with CRP levels in 
serum sample provided further supported this hypothesis. In most of the instances 
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where volunteers reported apparent sign of illness elevated CRP levels co-related 
with high siglec-9 expression levels. In a particular instance where volunteer was 
vaccinated with seasonal Influenza virus vaccine higher Siglec-9 expression levels 
matched with higher CRP levels. Serum CRP levels are used as biomarker for 
general inflammatory responses. Suggesting a direct relation between changes in 
immune system get directly reflected in monocyte surface siglec expression.  
In-vivo experiments where monocytes were co-cultured with purified viruses’, mere 
presence of virus particles (Influenza A, NDV, CMV, HAV-7, HAV-GBM, and 
Coxsackie B2 virus) resulted into changes in monocyte surface siglec expression. 
These changes in siglec expression were found not virus type dependent but virus 
dependent. Viruses belonging to either enveloped or non-enveloped group do not 
affect the siglecs expression similarly. Observed changes in monocyte siglec 
expression were regardless of the class of virus they incubated with. Such, changes 
in siglec expression in response to pathogens could be part of the host defence 
system as many pathogens are known to incorporate Sia-derivatives present on their 
surface for pathogenesis.  
The changes in siglec expression on monocyte cell surface in response to viruses 
are very dynamic as even 30min of incubation with viruses resulted into changes in 
siglec expression. Viral (Influenza A and HAV-7) dose and time of contact also 
contributed to these observed changes in siglec expression, viral load and incubation 
time is directly proportional with siglec expression changes on the monocyte cell 
surface. The incorporation of Sia into pathogens could subvert the host immune 
defence by engaging inhibitory siglecs (Varki and Angata, 2006). Such a race against 
the pathogen could have played a crucial role in evolving alternative activating 
siglecs from the inhibitory genes (Varki and Angata, 2006). The rapidly evolving 
siglec family could have developed a host defence system against these pathogens. 
It is also possible that incorporation of Sia into pathogens could destabilize the host 
immune defence by engaging inhibitory siglecs (Varki and Angata, 2006). In this way 
the siglecs could play a critical role in evolving siglec mediated immune system 
modulator processes. To confirm this hypothesis further work is needed. 
In an interesting siglec comparison between Causations volunteers verses Asians 
volunteers included in the study (15 individuals), shows that the Causations 
volunteers have a higher Siglec-9 expression level in comparison with the Asian 
volunteers. The study population is very little to conclude anything. It will be intresting 
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to investigate siglec expression among different races. This will put more light on the 
fact why some races are vulnerable to some pathogens while other show higher 
resistance. 
It was found out that the siglec expression on human mononuclear phagocytes alters 
in response with either Type-I or Type-II cytokines. It was also observed that siglec 
expression is further regulated by different cytokines (IFN?: increased siglec-1 and 
decreased siglec-5, -7 and -9; IL-4: increased siglec-7 and 9 and decreased siglec-
1). The exact mechanism of these siglec expression changes in response to 
cytokines needs to be elucidated.  
This may be relevant in tumour biology, because TAMs are often in an activated state 
compared to normal tissue macrophages (Putz and Mannel, 1995; Janicke and 
Mannel, 1990; Westenfelder et al., 1993). Therefore, it is feasible that cytokines 
present in the tumour environment modulate the Sia-dependent interaction of TAMs 
with tumour cells by regulating the siglec expression on these macrophages. Besides 
the expression pattern of siglecs, the competition of cis- and trans-interactions could 
also play an important role with regard to their function on TAMs, as described for 
siglec-2/CD22 on B-cells (O'Reilly et al., 2008). Indeed, the siglecs on mononuclear 
phagocytes are also found to be involved in cis-interactions. 
Many tumour markers have turned out to consist of carbohydrate structures. In 
particular, sialylated glycoconjugates have been discussed to be involved in the 
activation of TAMs (Brunetta et al., 2009). However, the nature of these 
corresponding Sia specific lectins present on the mononuclear phagocytes has not 
been elucidated. The siglec specificities for sialylated glycoconjugates and the 
presence of inhibitory signalling motifs in their cytoplasmic tails suggest that they 
could be involved in regulating Sia dependent activation of TAMs. A rapid release of 
cytokines by mononuclear phagocytes upon co-culture with K562 tumour cells was 
observed. Further investigation revealed that this activation is Sia dependent. 
Nevertheless, siglec-7 appears to bind glycoconjugates on K562 erythroleukemia 
cells in trans-, as it is clustered at contact sites with these cells. These 
glycoconjugates seem to bind with high affinity, since the siglec-Fc chimeras bind to 
K562 cells without creating multivalent binding sites by complexing with anti-Fc Ab to 
overcome the relatively low affinity of siglecs towards sialylated glycans and to obtain 
stable binding of siglec-Fc chimeras to potential target cells (Wu et al., 2009). The 
interaction of K562 glycoproteins was specific for each siglec. The highest amount of 
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bound glycoproteins was obtained with siglec-7, strongly suggesting that siglec-7 
plays a major role in the tumour cells recognition by TAMs. Since siglec-7 
preferentially binds to ?2,8-linked Sias (Ikemoto et al., 2003), it can be speculated 
that glycans containing this structure are present on these glycoproteins. Only little 
information is available on glycan structures on K562 surface glycoproteins and a 
detailed analysis of K562 cells glycosylation would be necessary to identify the 
recognition determinant(s) for siglec-7 in order to speculate on the functional 
consequences for cellular interactions.  
TAMs appear to be often in an activated state, since they release cytokines like IL-6 
(Terzidis-Trabelsi et al., 1992; Putz and Mannel, 1995; Janicke and Mannel, 1990). 
For example, TAMs isolated from renal cell carcinoma patients produced IL-6, tumour 
necrosis factor alpha (TNF?) and IL-1? without LPS stimulation, while monocytes 
isolated from the same patients hardly produced these cytokines without LPS 
stimulation (Ando et al., 2008). In agreement with previous reports (Strenge et al., 
1999b; Kelm et al., 2002; Varki and Angata, 2006b; Blixt et al., 2003) it is 
demonstrated that sialylated glycoconjugates on K562 cell surfaces induce secretion 
of cytokines by monocyte-derived macrophages in a Sia dependent manner. 
Furthermore it is shown that the release of IL-6 and IL-1? is rapid and involves the 
induction of mRNA synthesis. Apparently, this process does not appear to involve all 
parts of the well described Toll-like receptor pathway, since the induction of cytokine 
secretion by LPS takes longer. Usually, CD33rSiglecs have been considered to 
regulate immunological reactions by acting as inhibitory proteins.  
Interestingly, exposure to K562 cells had different effects on macrophages activated 
either with IL-4 or IFN?. Whereas macrophages treated with IL-4 did not secrete IL-6 
if stimulated by K562 cells, macrophages activated with IFN? responded with similar 
IL-6 secretion if co-cultured with K562 cells. However, the response of IFN? treated 
macrophages was Sia independent. One reason could be that these macrophages 
may recognise K562 cells by a different Sia dependent pathway.  
It is very likely that siglec-7 plays a role in Sia mediated activation of mononuclear 
phagocytes by K562 tumour cells, since anti siglec-7 mAb reduced the activation of 
mononuclear phagocyte by 30-40 %. Possibly, either the monoclonal antibody could 
not prevent the interaction between siglec-7 and sialoglycoconjugates on K562 cells 
completely or other siglecs present on mononuclear phagocytes are involved in the 
remaining activation processes. In addition, differential expression of corresponding 
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glycan structures on tumour cells, which can also differ in the linkage of the Sia 
and/or the structure of the underlying glycans, is possible. Furthermore it is known 
that modifications of functional groups of the Sia can significantly change the 
affinities of siglecs to these glycans. It is therefore possible that specific high affinity 
binding partners exist which mediate signalling through siglecs, although many 
potential glycosylated binding partners are present on tumour cells.  
In short, it can be said that siglec-7 is involved in the interaction between K562 
tumour cells and human mononuclear phagocytes. In future it will interesting to 
address the open questions of Sia-dependent activation of macrophages which may 
be mediated through other siglecs, like siglec-1 or 10, and whether this mechanism is 
also applicable for other human tumour cells. This could be of special interest, since 
tumour cells are often higher sialylated than corresponding healthy cells. A siglec-
mediated recognition of tumour cells by mononuclear phagocytes could describe a 
new mechanism of how phagocytes distinguish between healthy cells and tumour 
cells. 
In conclusion CD33rsiglecs represent a significant component of Ig superfamily 
proteins expressed in the innate immune system. Their molecular properties and the 
presence of tyrosine-based motifs are features that are shared with other receptors 
involved in fine tuning innate responses. This work suggests that siglecs control 
immunity by acting as inhibitory receptors. Data demonstrate that at least some 
members of the siglec family are also able to transduce inhibitory signals in myeloid 
cells. The restricted expression of siglecs on myeloid and lymphoid cells and the 
rapid progress in understanding their roles as cell signalling and endocytic receptors 
have made them attractive targets for cell-directed therapeutics. Siglec-specific 
antibodies have been the primary tool for targeting siglecs in vivo, but glycan-based 
probes of siglecs show promise as an alternative method for targeting these 
receptors. Success with ongoing clinical trials and animal models will probably spur 
increased interest in the development of therapeutics targeting this class of 
receptors. Challenges for the future are to elucidate the precise functions of siglecs in 
immune responses using genetic approaches where feasible to understand how cis 
and trans interactions with sialylated glycoconjugates contribute to their functions and 
to unravel the relevant signalling pathways. 
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